|Coronavirus disease 2019|
|Other names||COVID, (the) coronavirus|
Transmission and life-cycle of SARS-CoV-2, which causes COVID-19
|Symptoms||Fever, cough, fatigue, shortness of breath, vomiting, loss of taste or smell; some cases asymptomatic|
|Complications||Pneumonia, sepsis, ARDS, kidney failure, respiratory failure, pulmonary fibrosis, CKS, MIS-C, long COVID|
|Usual onset||2–14 days (typically 5) |
|Duration||5 days to chronic|
|Diagnostic method||RT‑PCR testing, CT scan, rapid antigen test|
|Prevention||Vaccination, face coverings, quarantine, social distancing, ventilation, hand washing|
|Treatment||Symptomatic and supportive|
|Part of a series on the|
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease quickly spread worldwide, resulting in the COVID-19 pandemic.
The symptoms of COVID‑19 are variable but often include fever, cough, headache, fatigue, breathing difficulties, loss of smell, and loss of taste. Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms. Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction). Older people are at a higher risk of developing severe symptoms. Some people continue to experience a range of effects (long COVID) for months after recovery, and damage to organs has been observed. Multi-year studies are underway to further investigate the long-term effects of the disease.
COVID‑19 transmits when people breathe air contaminated by droplets and small airborne particles containing the virus. The risk of breathing these is highest when people are in close proximity, but they can be inhaled over longer distances, particularly indoors. Transmission can also occur if contaminated fluids are splashed or sprayed in the eyes, nose, or mouth, or, more rarely, via contaminated surfaces. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.
Testing methods for COVID-19 to detect the virus's nucleic acid include real-time reverse transcription polymerase chain reaction (rRT‑PCR), transcription-mediated amplification, and reverse transcription loop-mediated isothermal amplification (RT‑LAMP) from a nasopharyngeal swab.
Several COVID-19 vaccines have been approved and distributed in various countries, which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While work is underway to develop drugs that inhibit the virus, the primary treatment is symptomatic. Management involves the treatment of symptoms through supportive care, isolation, and experimental measures.
During the initial outbreak in Wuhan, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus", with the disease sometimes called "Wuhan pneumonia". In the past, many diseases have been named after geographical locations, such as the Spanish flu, Middle East respiratory syndrome, and Zika virus. In January 2020, the World Health Organization (WHO) recommended 2019-nCoV and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations or groups of people in disease and virus names to prevent social stigma. The official names COVID‑19 and SARS-CoV-2 were issued by the WHO on 11 February 2020 with COVID-19 being shorthand for "coronavirus disease 2019". The WHO additionally uses "the COVID‑19 virus" and "the virus responsible for COVID‑19" in public communications.
Discover more about Nomenclature related topics
Symptoms and signs
The symptoms of COVID-19 are variable depending on the type of variant contracted, ranging from mild symptoms to a potentially fatal illness. Common symptoms include coughing, fever, loss of smell (anosmia) and taste (ageusia), with less common ones including headaches, nasal congestion and runny nose, muscle pain, sore throat, diarrhea, eye irritation, and toes swelling or turning purple, and in moderate to severe cases, breathing difficulties. People with the COVID-19 infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; and a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea. In people without prior ear, nose, or throat disorders, loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 88% of symptomatic cases.
Of people who show symptoms, 81% develop only mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging) that require hospitalization, and 5% of patients develop critical symptoms (respiratory failure, septic shock, or multiorgan dysfunction) requiring ICU admission. At least a third of the people who are infected with the virus do not develop noticeable symptoms at any point in time. These asymptomatic carriers tend not to get tested and can still spread the disease. Other infected people will develop symptoms later (called "pre-symptomatic") or have very mild symptoms and can also spread the virus.
As is common with infections, there is a delay between the moment a person first becomes infected and the appearance of the first symptoms. The median delay for COVID-19 is four to five days possibly being infectious on 1-4 of those days. Most symptomatic people experience symptoms within two to seven days after exposure, and almost all will experience at least one symptom within 12 days.
Most people recover from the acute phase of the disease. However, some people—over half of a cohort of home-isolated young adults identified in June 2021 continued to experience a range of effects, such as fatigue, for months even after recovery. This is the result of a condition called long COVID, which can be described as a range of persistent symptoms that continue for weeks and/or months at a time. Long-term damage to organs has also been observed after the onset of COVID-19. Multi-year studies are underway to further investigate the potential long-term effects of the disease.The Omicron variant became dominant in the U.S. in December 2021. Symptoms with the Omicron variant are less severe than they are with other variants.
Complications may include pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, septic shock, and death. Cardiovascular complications may include heart failure, arrhythmias (including atrial fibrillation), heart inflammation, and thrombosis, particularly venous thromboembolism. Approximately 20–30% of people who present with COVID‑19 have elevated liver enzymes, reflecting liver injury.
Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions). Following the infection, children may develop paediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, which can be fatal. In very rare cases, acute encephalopathy can occur, and it can be considered in those who have been diagnosed with COVID‑19 and have an altered mental status.
According to the US Centers for Disease Control and Prevention, pregnant women are at increased risk of becoming seriously ill from COVID‑19. This is because pregnant women with COVID‑19 appear to be more likely to develop respiratory and obstetric complications that can lead to miscarriage, premature delivery and intrauterine growth restriction.
Fungal infections such as aspergillosis, candidiasis, cryptococcosis and mucormycosis have been recorded in patients recovering from COVID‑19.
Discover more about Symptoms and signs related topics
COVID‑19 is caused by infection with a strain of coronavirus known as 'Severe Acute Respiratory Syndrome coronavirus 2' (SARS-CoV-2).
COVID-19 is mainly transmitted when people breathe in air contaminated by droplets/aerosols and small airborne particles containing the virus. Infected people exhale those particles as they breathe, talk, cough, sneeze, or sing. Transmission is more likely the more physically close people are. However, infection can occur over longer distances, particularly indoors.
Infectivity can begin four to five days before the onset of symptoms, although contact tracing typically begins only two to three days before symptom onset. Infected people can spread the disease even if they are pre-symptomatic or asymptomatic. Most commonly, the peak viral load in upper respiratory tract samples occurs close to the time of symptom onset and declines after the first week after symptoms begin. Current evidence suggests a duration of viral shedding and the period of infectiousness of up to ten days following symptom onset for people with mild to moderate COVID-19, and up to 20 days for persons with severe COVID-19, including immunocompromised people.
Infectious particles range in size from aerosols that remain suspended in the air for long periods of time to larger droplets that remain airborne briefly or fall to the ground. Additionally, COVID-19 research has redefined the traditional understanding of how respiratory viruses are transmitted. The largest droplets of respiratory fluid do not travel far, but can be inhaled or land on mucous membranes on the eyes, nose, or mouth to infect. Aerosols are highest in concentration when people are in close proximity, which leads to easier viral transmission when people are physically close, but airborne transmission can occur at longer distances, mainly in locations that are poorly ventilated; in those conditions small particles can remain suspended in the air for minutes to hours.The number of people generally infected by one infected person varies, but it is estimated that the R0 ("R nought" or "R zero") number is around 2.5. The disease often spreads in clusters, where infections can be traced back to an index case or geographical location. Often in these instances, superspreading events occur, where many people are infected by one person.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus. It was first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan. All structural features of the novel SARS-CoV-2 virus particle occur in related coronaviruses in nature, particularly in Rhinolophus sinicus aka Chinese horseshoe bats.
Outside the human body, the virus is destroyed by household soap, which bursts its protective bubble.
SARS-CoV-2 is closely related to the original SARS-CoV. It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13). The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S). The M protein of SARS-CoV-2 is about 98% similar to the M protein of bat SARS-CoV, maintains around 98% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only around 38% with the M protein of MERS-CoV.
The many thousands of SARS-CoV-2 variants are grouped into either clades or lineages. The WHO, in collaboration with partners, expert networks, national authorities, institutions and researchers, have established nomenclature systems for naming and tracking SARS-CoV-2 genetic lineages by GISAID, Nextstrain and Pango. The expert group convened by the WHO recommended the labelling of variants using letters of the Greek alphabet, for example, Alpha, Beta, Delta, and Gamma, giving the justification that they "will be easier and more practical to discussed by non-scientific audiences." Nextstrain divides the variants into five clades (19A, 19B, 20A, 20B, and 20C), while GISAID divides them into seven (L, O, V, S, G, GH, and GR). The Pango tool groups variants into lineages, with many circulating lineages being classed under the B.1 lineage.
Several notable variants of SARS-CoV-2 emerged throughout 2020. Cluster 5 emerged among minks and mink farmers in Denmark. After strict quarantines and a mink euthanasia campaign, the cluster was assessed to no longer be circulating among humans in Denmark as of 1 February 2021.
As of December 2021[update], there are five dominant variants of SARS-CoV-2 spreading among global populations: the Alpha variant (B.1.1.7, formerly called the UK variant), first found in London and Kent, the Beta variant (B.1.351, formerly called the South Africa variant), the Gamma variant (P.1, formerly called the Brazil variant), the Delta variant (B.1.617.2, formerly called the India variant), and the Omicron variant (B.1.1.529), which had spread to 57 countries as of 7 December.
Discover more about Cause related topics
The SARS-CoV-2 virus can infect a wide range of cells and systems of the body. COVID‑19 is most known for affecting the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs). The lungs are the organs most affected by COVID‑19 because the virus accesses host cells via the receptor for the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant on the surface of type II alveolar cells of the lungs. The virus uses a special surface glycoprotein called a "spike" to connect to the ACE2 receptor and enter the host cell.
Following viral entry, COVID‑19 infects the ciliated epithelium of the nasopharynx and upper airways.
One common symptom, loss of smell, results from infection of the support cells of the olfactory epithelium, with subsequent damage to the olfactory neurons. The involvement of both the central and peripheral nervous system in COVID‑19 has been reported in many medical publications. It is clear that many people with COVID-19 exhibit neurological or mental health issues. The virus is not detected in the central nervous system (CNS) of the majority of COVID-19 patients with neurological issues. However, SARS-CoV-2 has been detected at low levels in the brains of those who have died from COVID‑19, but these results need to be confirmed. While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain. The virus may also enter the bloodstream from the lungs and cross the blood–brain barrier to gain access to the CNS, possibly within an infected white blood cell.
Research conducted when Alpha was the dominant variant has suggested COVID-19 may cause brain damage. It is unknown if such damage is temporary or permanent, and whether Omicron has similar effects. Observed individuals infected with COVID-19 (most with mild cases) experienced an additional 0.2% to 2% of brain tissue lost in regions of the brain connected to the sense of smell compared with uninfected individuals, and the overall effect on the brain was equivalent on average to at least one extra year of normal ageing; infected individuals also scored lower on several cognitive tests. All effects were more pronounced among older ages.
The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium as well as endothelial cells and enterocytes of the small intestine.
The virus can cause acute myocardial injury and chronic damage to the cardiovascular system. An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China, and is more frequent in severe disease. Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart. ACE2 receptors are highly expressed in the heart and are involved in heart function.
A high incidence of thrombosis and venous thromboembolism occurs in people transferred to intensive care units with COVID‑19 infections, and may be related to poor prognosis. Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels caused by blood clots) may have a significant role in mortality, incidents of clots leading to pulmonary embolisms, and ischaemic events (strokes) within the brain found as complications leading to death in people infected with COVID‑19. Infection may initiate a chain of vasoconstrictive responses within the body, including pulmonary vasoconstriction – a possible mechanism in which oxygenation decreases during pneumonia. Furthermore, damage of arterioles and capillaries was found in brain tissue samples of people who died from COVID‑19.
COVID‑19 may also cause substantial structural changes to blood cells, sometimes persisting for months after hospital discharge. A low level of blood lymphocytes may result from the virus acting through ACE2-related entry into lymphocytes.
Another common cause of death is complications related to the kidneys. Early reports show that up to 30% of hospitalised patients both in China and in New York have experienced some injury to their kidneys, including some persons with no previous kidney problems.
Autopsies of people who died of COVID‑19 have found diffuse alveolar damage, and lymphocyte-containing inflammatory infiltrates within the lung.
Although SARS-CoV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, people with severe COVID‑19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL‑2, IL‑7, IL‑6, granulocyte-macrophage colony-stimulating factor (GM‑CSF), interferon gamma-induced protein 10 (IP‑10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1‑alpha (MIP‑1‑alpha), and tumour necrosis factor (TNF‑α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.
Interferon alpha plays a complex, Janus-faced role in the pathogenesis of COVID-19. Although it promotes the elimination of virus-infected cells, it also upregulates the expression of ACE-2, thereby facilitating the SARS-Cov2 virus to enter cells and to replicate. A competition of negative feedback loops (via protective effects of interferon alpha) and positive feedback loops (via upregulation of ACE-2) is assumed to determine the fate of patients suffering from COVID-19.
Additionally, people with COVID‑19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.
Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in people with COVID‑19. Lymphocytic infiltrates have also been reported at autopsy.
Viral and host factors
Multiple viral and host factors affect the pathogenesis of the virus. The S-protein, otherwise known as the spike protein, is the viral component that attaches to the host receptor via the ACE2 receptors. It includes two subunits: S1 and S2. S1 determines the virus-host range and cellular tropism via the receptor-binding domain. S2 mediates the membrane fusion of the virus to its potential cell host via the H1 and HR2, which are heptad repeat regions. Studies have shown that S1 domain induced IgG and IgA antibody levels at a much higher capacity. It is the focus spike proteins expression that are involved in many effective COVID‑19 vaccines.
The M protein is the viral protein responsible for the transmembrane transport of nutrients. It is the cause of the bud release and the formation of the viral envelope. The N and E protein are accessory proteins that interfere with the host's immune response.
Human angiotensin converting enzyme 2 (hACE2) is the host factor that SARS-CoV-2 virus targets causing COVID‑19. Theoretically, the usage of angiotensin receptor blockers (ARB) and ACE inhibitors upregulating ACE2 expression might increase morbidity with COVID‑19, though animal data suggest some potential protective effect of ARB; however no clinical studies have proven susceptibility or outcomes. Until further data is available, guidelines and recommendations for hypertensive patients remain.
The effect of the virus on ACE2 cell surfaces leads to leukocytic infiltration, increased blood vessel permeability, alveolar wall permeability, as well as decreased secretion of lung surfactants. These effects cause the majority of the respiratory symptoms. However, the aggravation of local inflammation causes a cytokine storm eventually leading to a systemic inflammatory response syndrome.
Among healthy adults not exposed to SARS-CoV-2, about 35% have CD4+ T cells that recognise the SARS-CoV-2 S protein (particularly the S2 subunit) and about 50% react to other proteins of the virus, suggesting cross-reactivity from previous common colds caused by other coronaviruses.
It is unknown whether different persons use similar antibody genes in response to COVID‑19.
Host cytokine response
The severity of the inflammation can be attributed to the severity of what is known as the cytokine storm. Levels of interleukin 1B, interferon-gamma, interferon-inducible protein 10, and monocyte chemoattractant protein 1 were all associated with COVID‑19 disease severity. Treatment has been proposed to combat the cytokine storm as it remains to be one of the leading causes of morbidity and mortality in COVID‑19 disease.
A cytokine storm is due to an acute hyperinflammatory response that is responsible for clinical illness in an array of diseases but in COVID‑19, it is related to worse prognosis and increased fatality. The storm causes acute respiratory distress syndrome, blood clotting events such as strokes, myocardial infarction, encephalitis, acute kidney injury, and vasculitis. The production of IL-1, IL-2, IL-6, TNF-alpha, and interferon-gamma, all crucial components of normal immune responses, inadvertently become the causes of a cytokine storm. The cells of the central nervous system, the microglia, neurons, and astrocytes, are also involved in the release of pro-inflammatory cytokines affecting the nervous system, and effects of cytokine storms toward the CNS are not uncommon.
There are many unknowns for pregnant women during the COVID-19 pandemic. Given that they are prone to have complications and severe disease infection with other types of coronaviruses, they have been identified as a vulnerable group and advised to take supplementary preventive measures.
Physiological responses to pregnancy can include:
- Immunological: The immunological response to COVID-19, like other viruses, depends on a working immune system. It adapts during pregnancy to allow the development of the foetus whose genetic load is only partially shared with their mother, leading to a different immunological reaction to infections during the course of pregnancy.
- Respiratory: Many factors can make pregnant women more vulnerable to hard respiratory infections. One of them is the total reduction of the lungs' capacity and inability to clear secretions.
- Coagulation: During pregnancy, there are higher levels of circulating coagulation factors, and the pathogenesis of SARS-CoV-2 infection can be implicated. The thromboembolic events with associated mortality are a risk for pregnant women.
However, from the evidence base, it is difficult to conclude whether pregnant women are at increased risk of grave consequences of this virus.
In addition to the above, other clinical studies have proved that SARS-CoV-2 can affect the period of pregnancy in different ways. On the one hand, there is little evidence of its impact up to 12 weeks gestation. On the other hand, COVID-19 infection may cause increased rates of unfavourable outcomes in the course of the pregnancy. Some examples of these could be foetal growth restriction, preterm birth, and perinatal mortality, which refers to the foetal death past 22 or 28 completed weeks of pregnancy as well as the death among live-born children up to seven completed days of life.
Unvaccinated women in later stages of pregnancy with COVID-19 are more likely than other patients to need very intensive care. Babies born to mothers with COVID-19 are more likely to have breathing problems. Pregnant women are strongly encouraged to get vaccinated.
Discover more about Pathophysiology related topics
COVID‑19 can provisionally be diagnosed on the basis of symptoms and confirmed using reverse transcription polymerase chain reaction (RT-PCR) or other nucleic acid testing of infected secretions. Along with laboratory testing, chest CT scans may be helpful to diagnose COVID‑19 in individuals with a high clinical suspicion of infection. Detection of a past infection is possible with serological tests, which detect antibodies produced by the body in response to the infection.
The standard methods of testing for presence of SARS-CoV-2 are nucleic acid tests, which detects the presence of viral RNA fragments. As these tests detect RNA but not infectious virus, its "ability to determine duration of infectivity of patients is limited." The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used. Results are generally available within hours. The WHO has published several testing protocols for the disease.
Several laboratories and companies have developed serological tests, which detect antibodies produced by the body in response to infection. Several have been evaluated by Public Health England and approved for use in the UK.
The University of Oxford's CEBM has pointed to mounting evidence that "a good proportion of 'new' mild cases and people re-testing positives after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with" and have called for "an international effort to standardize and periodically calibrate testing" In September 2020, the UK government issued "guidance for procedures to be implemented in laboratories to provide assurance of positive SARS-CoV-2 RNA results during periods of low prevalence, when there is a reduction in the predictive value of positive test results".
Chest CT scans may be helpful to diagnose COVID‑19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening. Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection. Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses. Characteristic imaging features on chest radiographs and computed tomography (CT) of people who are symptomatic include asymmetric peripheral ground-glass opacities without pleural effusions.
Many groups have created COVID‑19 datasets that include imagery such as the Italian Radiological Society which has compiled an international online database of imaging findings for confirmed cases. Due to overlap with other infections such as adenovirus, imaging without confirmation by rRT-PCR is of limited specificity in identifying COVID‑19. A large study in China compared chest CT results to PCR and demonstrated that though imaging is less specific for the infection, it is faster and more sensitive.
In late 2019, the WHO assigned emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID‑19 without lab-confirmed SARS-CoV-2 infection.
The main pathological findings at autopsy are:
- Macroscopy: pericarditis, lung consolidation and pulmonary oedema
- Lung findings:
- minor serous exudation, minor fibrin exudation
- pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation
- diffuse alveolar damage (DAD) with diffuse alveolar exudates. DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxaemia.
- organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis
- plasmocytosis in BAL
- Blood and vessels: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction, endotheliitis, hemophagocytosis
- Heart: cardiac muscle cell necrosis
- Liver: microvesicular steatosis
- Nose: shedding of olfactory epithelium
- Brain: infarction
- Kidneys: acute tubular damage.
- Spleen: white pulp depletion.
Discover more about Diagnosis related topics
Preventive measures to reduce the chances of infection include getting vaccinated, staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, ventilating indoor spaces, managing potential exposure durations, washing hands with soap and water often and for at least twenty seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.
Those diagnosed with COVID‑19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.
The first COVID‑19 vaccine was granted regulatory approval on 2 December 2020 by the UK medicines regulator MHRA. It was evaluated for emergency use authorization (EUA) status by the US FDA, and in several other countries. Initially, the US National Institutes of Health guidelines do not recommend any medication for prevention of COVID‑19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial. Without a vaccine, other prophylactic measures, or effective treatments, a key part of managing COVID‑19 is trying to decrease and delay the epidemic peak, known as "flattening the curve". This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of active cases, and delaying additional cases until effective treatments or a vaccine become available.
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).
Face masks and respiratory hygiene
The WHO and the US CDC recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain. This recommendation is meant to reduce the spread of the disease by asymptomatic and pre-symptomatic individuals and is complementary to established preventive measures such as social distancing. Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing. A face covering without vents or holes will also filter out particles containing the virus from inhaled and exhaled air, reducing the chances of infection. However, if the mask includes an exhalation valve, a wearer that is infected (and possibly asymptomatic) may transmit the virus through the valve. Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus.
Masks are also strongly recommended for those who may have been infected and those taking care of someone who may have the disease. When not wearing a mask, the CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. Proper hand hygiene after any cough or sneeze is encouraged. Healthcare professionals interacting directly with people who have COVID‑19 are advised to use respirators at least as protective as NIOSH-certified N95 or equivalent, in addition to other personal protective equipment.
Indoor ventilation and avoiding crowded indoor spaces
The CDC recommends that crowded indoor spaces should be avoided. When indoors, increasing the rate of air change, decreasing recirculation of air and increasing the use of outdoor air can reduce transmission. The WHO recommends ventilation and air filtration in public spaces to help clear out infectious aerosols.
Exhaled respiratory particles can build-up within enclosed spaces with inadequate ventilation. The risk of COVID‑19 infection increases especially in spaces where people engage in physical exertion or raise their voice (e.g., exercising, shouting, singing) as this increases exhalation of respiratory droplets. Prolonged exposure to these conditions, typically more than 15 minutes, leads to higher risk of infection.
Displacement ventilation with large natural inlets can move stale air directly to the exhaust in laminar flow while significantly reducing the concentration of droplets and particles. Passive ventilation reduces energy consumption and maintenance costs but may lack controllability and heat recovery. Displacement ventilation can also be achieved mechanically with higher energy and maintenance costs. The use of large ducts and openings helps to prevent mixing in closed environments. Recirculation and mixing should be avoided because recirculation prevents dilution of harmful particles and redistributes possibly contaminated air, and mixing increases the concentration and range of infectious particles and keeps larger particles in the air.
Hand-washing and hygiene
Thorough hand hygiene after any cough or sneeze is required. The WHO also recommends that individuals wash hands often with soap and water for at least twenty seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose. When soap and water are not available, the CDC recommends using an alcohol-based hand sanitiser with at least 60% alcohol. For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis." Glycerol is added as a humectant.
Social distancing (also known as physical distancing) includes infection control actions intended to slow the spread of the disease by minimising close contact between individuals. Methods include quarantines; travel restrictions; and the closing of schools, workplaces, stadiums, theatres, or shopping centres. Individuals may apply social distancing methods by staying at home, limiting travel, avoiding crowded areas, using no-contact greetings, and physically distancing themselves from others. Many governments are mandating or recommending social distancing in regions affected by the outbreak.
Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing. In the United States, the prisoner population is ageing and many of them are at high risk for poor outcomes from COVID‑19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.
After being expelled from the body, coronaviruses can survive on surfaces for hours to days. If a person touches the dirty surface, they may deposit the virus at the eyes, nose, or mouth where it can enter the body and cause infection. Evidence indicates that contact with infected surfaces is not the main driver of COVID‑19, leading to recommendations for optimised disinfection procedures to avoid issues such as the increase of antimicrobial resistance through the use of inappropriate cleaning products and processes. Deep cleaning and other surface sanitation has been criticised as hygiene theatre, giving a false sense of security against something primarily spread through the air.
The amount of time that the virus can survive depends significantly on the type of surface, the temperature, and the humidity. Coronaviruses die very quickly when exposed to the UV light in sunlight. Like other enveloped viruses, SARS-CoV-2 survives longest when the temperature is at room temperature or lower, and when the relative humidity is low (
On many surfaces, including glass, some types of plastic, stainless steel, and skin, the virus can remain infective for several days indoors at room temperature, or even about a week under ideal conditions. On some surfaces, including cotton fabric and copper, the virus usually dies after a few hours. The virus dies faster on porous surfaces than on non-porous surfaces due to capillary action within pores and faster aerosol droplet evaporation. However, of the many surfaces tested, two with the longest survival times are N95 respirator masks and surgical masks, both of which are considered porous surfaces.
The CDC says that in most situations, cleaning surfaces with soap or detergent, not disinfecting, is enough to reduce risk of transmission. The CDC recommends that if a COVID‑19 case is suspected or confirmed at a facility such as an office or day care, all areas such as offices, bathrooms, common areas, shared electronic equipment like tablets, touch screens, keyboards, remote controls, and ATMs used by the ill persons should be disinfected. Surfaces may be decontaminated with 62–71 per cent ethanol, 50–100 per cent isopropanol, 0.1 per cent sodium hypochlorite, 0.5 per cent hydrogen peroxide, 0.2–7.5 per cent povidone-iodine, or 50–200 ppm hypochlorous acid. Other solutions, such as benzalkonium chloride and chlorhexidine gluconate, are less effective. Ultraviolet germicidal irradiation may also be used, although popular devices require 5–10 min exposure and may deteriorate some materials over time. A datasheet comprising the authorised substances to disinfection in the food industry (including suspension or surface tested, kind of surface, use dilution, disinfectant and inoculum volumes) can be seen in the supplementary material of.
Self-isolation at home has been recommended for those diagnosed with COVID‑19 and those who suspect they have been infected. Health agencies have issued detailed instructions for proper self-isolation. Many governments have mandated or recommended self-quarantine for entire populations. The strongest self-quarantine instructions have been issued to those in high-risk groups. Those who may have been exposed to someone with COVID‑19 and those who have recently travelled to a country or region with the widespread transmission have been advised to self-quarantine for 14 days from the time of last possible exposure.
A 2021 Cochrane rapid review found that based upon low-certainty evidence, international travel-related control measures such as restricting cross-border travel may help to contain the spread of COVID‑19. Additionally, symptom/exposure-based screening measures at borders may miss many positive cases. While test-based border screening measures may be more effective, it could also miss many positive cases if only conducted upon arrival without follow-up. The review concluded that a minimum 10-day quarantine may be beneficial in preventing the spread of COVID‑19 and may be more effective if combined with an additional control measure like border screening.
Discover more about Prevention related topics
Non-pharmaceutical intervention (epidemiology)
Pandemic predictions and preparations prior to the COVID-19 pandemic
Medicines and Healthcare products Regulatory Agency
National Institutes of Health
Face masks during the COVID-19 pandemic
Although several medications have been approved in different countries as of April 2022, not all countries have these medications. Patients with mild to moderate symptoms who are in the risk groups can take nirmatrelvir/ritonavir (marketed as Paxlovid) or remdesivir, either of which reduces the risk of serious illness or hospitalization. In the US, the Biden Administration COVID-19 action plan includes the Test to Treat initiative, where people can go to a pharmacy, take a COVID test, and immediately receive free Paxlovid if they test positive.
Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the estimated millions of immunocompromised persons who are unlikely to respond robustly to vaccination, treatment remains important. The cornerstone of management of COVID-19 has been supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support and prone positioning as needed, and medications or devices to support other affected vital organs.
Most cases of COVID-19 are mild. In these, supportive care includes medication such as paracetamol or NSAIDs to relieve symptoms (fever, body aches, cough), proper intake of fluids, rest, and nasal breathing. Good personal hygiene and a healthy diet are also recommended. As of April 2020 the U.S. Centers for Disease Control and Prevention (CDC) recommended that those who suspect they are carrying the virus isolate themselves at home and wear a face mask.As of November 2020 use of the glucocorticoid dexamethasone had been strongly recommended in those severe cases treated in hospital with low oxygen levels, to reduce the risk of death. Noninvasive ventilation and, ultimately, admission to an intensive care unit for mechanical ventilation may be required to support breathing. Extracorporeal membrane oxygenation (ECMO) has been used to address respiratory failure, but its benefits are still under consideration. Some of the cases of severe disease course are caused by systemic hyper-inflammation, the so-called cytokine storm.
Discover more about Treatment related topics
Prognosis and risk factors
The severity of COVID‑19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. In 3–4% of cases (7.4% for those over age 65) symptoms are severe enough to cause hospitalisation. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks. The Italian Istituto Superiore di Sanità reported that the median time between the onset of symptoms and death was twelve days, with seven being hospitalised. However, people transferred to an ICU had a median time of ten days between hospitalisation and death. Abnormal sodium levels during hospitalization with COVID-19 are associated with poor prognoses: high sodium with a greater risk of death, and low sodium with an increased chance of needing ventilator support. Prolonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID‑19 and with a transfer to ICU.
Some early studies suggest 10% to 20% of people with COVID‑19 will experience symptoms lasting longer than a month. A majority of those who were admitted to hospital with severe disease report long-term problems including fatigue and shortness of breath. On 30 October 2020, WHO chief Tedros Adhanom warned that "to a significant number of people, the COVID virus poses a range of serious long-term effects." He has described the vast spectrum of COVID‑19 symptoms that fluctuate over time as "really concerning". They range from fatigue, a cough and shortness of breath, to inflammation and injury of major organs – including the lungs and heart, and also neurological and psychologic effects. Symptoms often overlap and can affect any system in the body. Infected people have reported cyclical bouts of fatigue, headaches, months of complete exhaustion, mood swings, and other symptoms. Tedros therefore concluded that a strategy of achieving herd immunity by infection, rather than vaccination, is "morally unconscionable and unfeasible".
In terms of hospital readmissions about 9% of 106,000 individuals had to return for hospital treatment within two months of discharge. The average to readmit was eight days since first hospital visit. There are several risk factors that have been identified as being a cause of multiple admissions to a hospital facility. Among these are advanced age (above 65 years of age) and presence of a chronic condition such as diabetes, COPD, heart failure or chronic kidney disease.
According to scientific reviews smokers are more likely to require intensive care or die compared to non-smokers. Acting on the same ACE2 pulmonary receptors affected by smoking, air pollution has been correlated with the disease. Short term and chronic exposure to air pollution seems to enhance morbidity and mortality from COVID‑19. Pre-existing heart and lung diseases and also obesity, especially in conjunction with fatty liver disease, contributes to an increased health risk of COVID‑19.
It is also assumed that those that are immunocompromised are at higher risk of getting severely sick from SARS-CoV-2. One research study that looked into the COVID‑19 infections in hospitalised kidney transplant recipients found a mortality rate of 11%.
Men with untreated hypogonadism were 2.4 times more likely than men with eugonadism to be hospitalized if they contracted COVID-19; Hypogonad men treated with testosterone were less likely to be hospitalized for COVID-19 than men who were not treated for hypogonadism.
Genetic risk factors
Genetics plays an important role in the ability to fight off Covid. For instance, those that do not produce detectable type I interferons or produce auto-antibodies against these may get much sicker from COVID‑19. Genetic screening is able to detect interferon effector genes. Some genetic variants are risk factors in specific populations. For instance, and allele of the DOCK2 gene (dedicator of cytokinesis 2 gene) is a common risk factor in Asian populations but much less common in Europe. The mutation leads to lower expression of DOCK2 especially in younger patients with severe Covid. In fact, many other genes and genetic variants have been found that determine the outcome of SARS-CoV-2 infections.
While very young children have experienced lower rates of infection, older children have a rate of infection that is similar to the population as a whole. Children are likely to have milder symptoms and are at lower risk of severe disease than adults. The CDC reports that in the US roughly a third of hospitalised children were admitted to the ICU, while a European multinational study of hospitalised children from June 2020, found that about 8% of children admitted to a hospital needed intensive care. Four of the 582 children (0.7%) in the European study died, but the actual mortality rate may be "substantially lower" since milder cases that did not seek medical help were not included in the study.
Some early studies suggest that 10–20% of people with COVID‑19 will experience symptoms lasting longer than a month. A majority of those who were admitted to hospital with severe disease report long-term problems, including fatigue and shortness of breath. About 5–10% of patients admitted to hospital progress to severe or critical disease, including pneumonia and acute respiratory failure.
By a variety of mechanisms, the lungs are the organs most affected in COVID‑19. In people requiring hospital admission, up to 98% of CT scans performed show lung abnormalities after 28 days of illness even if they had clinically improved.
People with advanced age, severe disease, prolonged ICU stays, or who smoke are more likely to have long-lasting effects, including pulmonary fibrosis. Overall, approximately one-third of those investigated after four weeks will have findings of pulmonary fibrosis or reduced lung function as measured by DLCO, even in asymptomatic people, but with the suggestion of continuing improvement with the passing of more time. After severe disease, lung function can take anywhere from three months to a year or more to return to previous levels.
The risks of cognitive deficit, dementia, psychotic disorders, and epilepsy or seizures persists at an increased level two years after infection.
The immune response by humans to SARS-CoV-2 virus occurs as a combination of the cell-mediated immunity and antibody production, just as with most other infections. B cells interact with T cells and begin dividing before selection into the plasma cell, partly on the basis of their affinity for antigen. Since SARS-CoV-2 has been in the human population only since December 2019, it remains unknown if the immunity is long-lasting in people who recover from the disease. The presence of neutralising antibodies in blood strongly correlates with protection from infection, but the level of neutralising antibody declines with time. Those with asymptomatic or mild disease had undetectable levels of neutralising antibody two months after infection. In another study, the level of neutralising antibodies fell four-fold one to four months after the onset of symptoms. However, the lack of antibodies in the blood does not mean antibodies will not be rapidly produced upon reexposure to SARS-CoV-2. Memory B cells specific for the spike and nucleocapsid proteins of SARS-CoV-2 last for at least six months after the appearance of symptoms.
As of August 2021, reinfection with COVID‑19 was possible but uncommon. The first case of reinfection was documented in August 2020. A systematic review found 17 cases of confirmed reinfection in medical literature as of May 2021. With the Omicron variant, as of 2022, reinfections have become common, albeit it is unclear how common. COVID-19 reinfections are thought to likely be less severe than primary infections, especially if one was previously infected by the same variant.
Discover more about Prognosis and risk factors related topics
Several measures are commonly used to quantify mortality. These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health.
The mortality rate reflects the number of deaths within a specific demographic group divided by the population of that demographic group. Consequently, the mortality rate reflects the prevalence as well as the severity of the disease within a given population. Mortality rates are highly correlated to age, with relatively low rates for young people and relatively high rates among the elderly. In fact, one relevant factor of mortality rates is the age structure of the countries' populations. For example, the case fatality rate for COVID‑19 is lower in India than in the US since India's younger population represents a larger percentage than in the US.
Case fatality rate
The case fatality rate (CFR) reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is 1.02% (6,881,955/676,609,955) as of 10 March 2023. The number varies by region.
Total confirmed cases of COVID‑19 per million people
Total confirmed deaths due to COVID‑19 per million people
Infection fatality rate
A key metric in gauging the severity of COVID‑19 is the infection fatality rate (IFR), also referred to as the infection fatality ratio or infection fatality risk. This metric is calculated by dividing the total number of deaths from the disease by the total number of infected individuals; hence, in contrast to the CFR, the IFR incorporates asymptomatic and undiagnosed infections as well as reported cases.
A December 2020 systematic review and meta-analysis estimated that population IFR during the first wave of the pandemic was about 0.5% to 1% in many locations (including France, Netherlands, New Zealand, and Portugal), 1% to 2% in other locations (Australia, England, Lithuania, and Spain), and exceeded 2% in Italy. That study also found that most of these differences in IFR reflected corresponding differences in the age composition of the population and age-specific infection rates; in particular, the metaregression estimate of IFR is very low for children and younger adults (e.g., 0.002% at age 10 and 0.01% at age 25) but increases progressively to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85. These results were also highlighted in a December 2020 report issued by the WHO.
An analysis of those IFR rates indicates that COVID‑19 is hazardous not only for the elderly but also for middle-aged adults, for whom the infection fatality rate of COVID-19 is two orders of magnitude greater than the annualised risk of a fatal automobile accident and far more dangerous than seasonal influenza.
Earlier estimates of IFR
At an early stage of the pandemic, the World Health Organization reported estimates of IFR between 0.3% and 1%. On 2 July, The WHO's chief scientist reported that the average IFR estimate presented at a two-day WHO expert forum was about 0.6%. In August, the WHO found that studies incorporating data from broad serology testing in Europe showed IFR estimates converging at approximately 0.5–1%. Firm lower limits of IFRs have been established in a number of locations such as New York City and Bergamo in Italy since the IFR cannot be less than the population fatality rate. (After sufficient time however, people can get reinfected). As of 10 July, in New York City, with a population of 8.4 million, 23,377 individuals (18,758 confirmed and 4,619 probable) have died with COVID‑19 (0.3% of the population). Antibody testing in New York City suggested an IFR of ≈0.9%, and ≈1.4%. In Bergamo province, 0.6% of the population has died. In September 2020, the U.S. Centers for Disease Control and Prevention (CDC) reported preliminary estimates of age-specific IFRs for public health planning purposes.
|Percentage of infected people who are hospitalised|
|Percentage of hospitalised people who go to Intensive Care Unit|
|Percent of hospitalised people who die|
|Percent of infected people who die – infection fatality rate (IFR)|
|Numbers in parentheses are 95% credible intervals for the estimates.|
COVID‑19 case fatality rates are higher among men than women in most countries. However, in a few countries like India, Nepal, Vietnam, and Slovenia the fatality cases are higher in women than men. Globally, men are more likely to be admitted to the ICU and more likely to die. One meta-analysis found that globally, men were more likely to get COVID‑19 than women; there were approximately 55 men and 45 women per 100 infections (CI: 51.43–56.58).
The Chinese Center for Disease Control and Prevention reported the death rate was 2.8% for men and 1.7% for women. Later reviews in June 2020 indicated that there is no significant difference in susceptibility or in CFR between genders. One review acknowledges the different mortality rates in Chinese men, suggesting that it may be attributable to lifestyle choices such as smoking and drinking alcohol rather than genetic factors. Smoking, which in some countries like China is mainly a male activity, is a habit that contributes to increasing significantly the case fatality rates among men. Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men. In Europe as of February 2020, 57% of the infected people were men and 72% of those died with COVID‑19 were men. As of April 2020, the US government is not tracking sex-related data of COVID‑19 infections. Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
In the US, a greater proportion of deaths due to COVID‑19 have occurred among African Americans and other minority groups. Structural factors that prevent them from practising social distancing include their concentration in crowded substandard housing and in "essential" occupations such as retail grocery workers, public transit employees, health-care workers and custodial staff. Greater prevalence of lacking health insurance and care of underlying conditions such as diabetes, hypertension, and heart disease also increase their risk of death. Similar issues affect Native American and Latino communities. On the one hand, in the Dominican Republic there is a clear example of both gender and ethnic inequality. In this Latin American territory, there is great inequality and precariousness that especially affects Dominican women, with greater emphasis on those of Haitian descent. According to a US health policy non-profit, 34% of American Indian and Alaska Native People (AIAN) non-elderly adults are at risk of serious illness compared to 21% of white non-elderly adults. The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water.
Leaders have called for efforts to research and address the disparities. In the UK, a greater proportion of deaths due to COVID‑19 have occurred in those of a Black, Asian, and other ethnic minority background. More severe impacts upon patients including the relative incidence of the necessity of hospitalisation requirements, and vulnerability to the disease has been associated via DNA analysis to be expressed in genetic variants at chromosomal region 3, features that are associated with European Neanderthal heritage. That structure imposes greater risks that those affected will develop a more severe form of the disease. The findings are from Professor Svante Pääbo and researchers he leads at the Max Planck Institute for Evolutionary Anthropology and the Karolinska Institutet. This admixture of modern human and Neanderthal genes is estimated to have occurred roughly between 50,000 and 60,000 years ago in Southern Europe.
Biological factors (immune response) and the general behaviour (habits) can strongly determine the consequences of COVID‑19. Most of those who die of COVID‑19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease. According to March data from the United States, 89% of those hospitalised had preexisting conditions. The Italian Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available, 96.1% of people had at least one comorbidity with the average person having 3.4 diseases. According to this report the most common comorbidities are hypertension (66% of deaths), type 2 diabetes (29.8% of deaths), ischaemic heart disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths).
Most critical respiratory comorbidities according to the US Centers for Disease Control and Prevention (CDC), are: moderate or severe asthma, pre-existing COPD, pulmonary fibrosis, cystic fibrosis. Evidence stemming from meta-analysis of several smaller research papers also suggests that smoking can be associated with worse outcomes. When someone with existing respiratory problems is infected with COVID‑19, they might be at greater risk for severe symptoms. COVID‑19 also poses a greater risk to people who misuse opioids and amphetamines, insofar as their drug use may have caused lung damage.
In August 2020, the CDC issued a caution that tuberculosis (TB) infections could increase the risk of severe illness or death. The WHO recommended that people with respiratory symptoms be screened for both diseases, as testing positive for COVID‑19 could not rule out co-infections. Some projections have estimated that reduced TB detection due to the pandemic could result in 6.3 million additional TB cases and 1.4 million TB-related deaths by 2025.
Discover more about Mortality related topics
COVID-19 pandemic death rates by country
Case fatality rate
Centers for Disease Control and Prevention
Gendered impact of the COVID-19 pandemic
COVID-19 pandemic in France
COVID-19 pandemic on Diamond Princess
Chinese Center for Disease Control and Prevention
The virus is thought to be of natural animal origin, most likely through spillover infection. A joint-study conducted in early 2021 by the People's Republic of China and the World Health Organization indicated that the virus descended from a coronavirus that infects wild bats, and likely spread to humans through an intermediary wildlife host. There are several theories about where the index case originated and investigations into the origin of the pandemic are ongoing. According to articles published in July 2022 in Science, virus transmission into humans occurred through two spillover events in November 2019 and was likely due to live wildlife trade on the Huanan wet market in the city of Wuhan (Hubei, China). Doubts about the conclusions have mostly centered on the precise site of spillover. Earlier phylogenetics estimated that SARS-CoV-2 arose in October or November 2019. A phylogenetic algorithm analysis suggested that the virus may have been circulating in Guangdong before Wuhan.
Most scientists believe the virus spilled into human populations through natural zoonosis, similar to the SARS-CoV-1 and MERS-CoV outbreaks, and consistent with other pandemics in human history. Available evidence suggests that the SARS-CoV-2 virus was originally harbored by bats, and spread to humans multiple times from infected wild animals at the Huanan Seafood Market in Wuhan in December 2019. A minority of scientists and some members of the U.S intelligence community believe the virus may have been unintentionally leaked from a laboratory such as the Wuhan Institute of Virology. The US intelligence community has mixed views on the issue, but overall agrees with the scientific consensus that the virus was not developed as a biological weapon and is unlikely to have been genetically engineered. There is no evidence SARS-CoV-2 existed in any laboratory prior to the pandemic.
The first confirmed human infections were in Wuhan. A study of the first 41 cases of confirmed COVID‑19, published in January 2020 in The Lancet, reported the earliest date of onset of symptoms as 1 December 2019. Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019. Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020. According to official Chinese sources, these were mostly linked to the Huanan Seafood Wholesale Market, which also sold live animals. In May 2020, George Gao, the director of the CDC, said animal samples collected from the seafood market had tested negative for the virus, indicating that the market was the site of an early superspreading event, but that it was not the site of the initial outbreak. Traces of the virus have been found in wastewater samples that were collected in Milan and Turin, Italy, on 18 December 2019.
By December 2019, the spread of infection was almost entirely driven by human-to-human transmission. The number of COVID-19 cases in Hubei gradually increased, reaching sixty by 20 December, and at least 266 by 31 December. On 24 December, Wuhan Central Hospital sent a bronchoalveolar lavage fluid (BAL) sample from an unresolved clinical case to sequencing company Vision Medicals. On 27 and 28 December, Vision Medicals informed the Wuhan Central Hospital and the Chinese CDC of the results of the test, showing a new coronavirus. A pneumonia cluster of unknown cause was observed on 26 December and treated by the doctor Zhang Jixian in Hubei Provincial Hospital, who informed the Wuhan Jianghan CDC on 27 December. On 30 December, a test report addressed to Wuhan Central Hospital, from company CapitalBio Medlab, stated an erroneous positive result for SARS, causing a group of doctors at Wuhan Central Hospital to alert their colleagues and relevant hospital authorities of the result. The Wuhan Municipal Health Commission issued a notice to various medical institutions on "the treatment of pneumonia of unknown cause" that same evening. Eight of these doctors, including Li Wenliang (punished on 3 January), were later admonished by the police for spreading false rumours and another, Ai Fen, was reprimanded by her superiors for raising the alarm.
The Wuhan Municipal Health Commission made the first public announcement of a pneumonia outbreak of unknown cause on 31 December, confirming 27 cases – enough to trigger an investigation.
During the early stages of the outbreak, the number of cases doubled approximately every seven and a half days. In early and mid-January 2020, the virus spread to other Chinese provinces, helped by the Chinese New Year migration and Wuhan being a transport hub and major rail interchange. On 20 January, China reported nearly 140 new cases in one day, including two people in Beijing and one in Shenzhen. Later official data shows 6,174 people had already developed symptoms by then, and more may have been infected. A report in The Lancet on 24 January indicated human transmission, strongly recommended personal protective equipment for health workers, and said testing for the virus was essential due to its "pandemic potential". On 30 January, the WHO declared COVID-19 a Public Health Emergency of International Concern. By this time, the outbreak spread by a factor of 100 to 200 times.
Italy had its first confirmed cases on 31 January 2020, two tourists from China. Italy overtook China as the country with the most deaths on 19 March 2020. By 26 March the United States had overtaken China and Italy with the highest number of confirmed cases in the world. Research on coronavirus genomes indicates the majority of COVID-19 cases in New York came from European travellers, rather than directly from China or any other Asian country. Retesting of prior samples found a person in France who had the virus on 27 December 2019, and a person in the United States who died from the disease on 6 February 2020.
RT-PCR testing of untreated wastewater samples from Brazil and Italy have suggested detection of SARS-CoV-2 as early as November and December 2019, respectively, but the methods of such sewage studies have not been optimised, many have not been peer-reviewed, details are often missing, and there is a risk of false positives due to contamination or if only one gene target is detected. A September 2020 review journal article said, "The possibility that the COVID‑19 infection had already spread to Europe at the end of last year is now indicated by abundant, even if partially circumstantial, evidence," including pneumonia case numbers and radiology in France and Italy in November and December.
As of 1 October 2021[update], Reuters reported that it had estimated the worldwide total number of deaths due to COVID‑19 to have exceeded five million.
Discover more about History related topics
After the initial outbreak of COVID‑19, misinformation and disinformation regarding the origin, scale, prevention, treatment, and other aspects of the disease rapidly spread online.
In September 2020, the US Centers for Disease Control and Prevention (CDC) published preliminary estimates of the risk of death by age groups in the United States, but those estimates were widely misreported and misunderstood.
Discover more about Misinformation related topics
Humans appear to be capable of spreading the virus to some other animals, a type of disease transmission referred to as zooanthroponosis.
Some pets, especially cats and ferrets, can catch this virus from infected humans. Symptoms in cats include respiratory (such as a cough) and digestive symptoms. Cats can spread the virus to other cats, and may be able to spread the virus to humans, but cat-to-human transmission of SARS-CoV-2 has not been proven. Compared to cats, dogs are less susceptible to this infection. Behaviours which increase the risk of transmission include kissing, licking, and petting the animal.
The virus does not appear to be able to infect pigs, ducks, or chickens at all. Mice, rats, and rabbits, if they can be infected at all, are unlikely to be involved in spreading the virus.
Tigers and lions in zoos have become infected as a result of contact with infected humans. As expected, monkeys and great ape species such as orangutans can also be infected with the COVID‑19 virus.
Minks, which are in the same family as ferrets, have been infected. Minks may be asymptomatic, and can also spread the virus to humans. Multiple countries have identified infected animals in mink farms. Denmark, a major producer of mink pelts, ordered the slaughter of all minks over fears of viral mutations, following an outbreak referred to as Cluster 5. A vaccine for mink and other animals is being researched.
Discover more about Other species related topics
International research on vaccines and medicines in COVID‑19 is underway by government organisations, academic groups, and industry researchers. The CDC has classified it to require a BSL3 grade laboratory. There has been a great deal of COVID‑19 research, involving accelerated research processes and publishing shortcuts to meet the global demand.
As of December 2020[update], hundreds of clinical trials have been undertaken, with research happening on every continent except Antarctica. As of November 2020[update], more than 200 possible treatments have been studied in humans.
Transmission and prevention research
Modelling research has been conducted with several objectives, including predictions of the dynamics of transmission, diagnosis and prognosis of infection, estimation of the impact of interventions, or allocation of resources. Modelling studies are mostly based on compartmental models in epidemiology, estimating the number of infected people over time under given conditions. Several other types of models have been developed and used during the COVID‑19 pandemic including computational fluid dynamics models to study the flow physics of COVID‑19, retrofits of crowd movement models to study occupant exposure, mobility-data based models to investigate transmission, or the use of macroeconomic models to assess the economic impact of the pandemic. Further, conceptual frameworks from crisis management research have been applied to better understand the effects of COVID‑19 on organisations worldwide.
Repurposed antiviral drugs make up most of the research into COVID‑19 treatments. Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.
In March 2020, the World Health Organization (WHO) initiated the Solidarity trial to assess the treatment effects of some promising drugs: an experimental drug called remdesivir; anti-malarial drugs chloroquine and hydroxychloroquine; two anti-HIV drugs, lopinavir/ritonavir; and interferon-beta. More than 300 active clinical trials are underway as of April 2020.
Research on the antimalarial drugs hydroxychloroquine and chloroquine showed that they were ineffective at best, and that they may reduce the antiviral activity of remdesivir. By May 2020[update], France, Italy, and Belgium had banned the use of hydroxychloroquine as a COVID‑19 treatment.
In June, initial results from the randomised RECOVERY Trial in the United Kingdom showed that dexamethasone reduced mortality by one third for people who are critically ill on ventilators and one fifth for those receiving supplemental oxygen. Because this is a well-tested and widely available treatment, it was welcomed by the WHO, which is in the process of updating treatment guidelines to include dexamethasone and other steroids. Based on those preliminary results, dexamethasone treatment has been recommended by the NIH for patients with COVID‑19 who are mechanically ventilated or who require supplemental oxygen but not in patients with COVID‑19 who do not require supplemental oxygen.
In September 2020, the WHO released updated guidance on using corticosteroids for COVID‑19. The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID‑19 (strong recommendation, based on moderate certainty evidence). The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID‑19 (conditional recommendation, based on low certainty evidence). The updated guidance was based on a meta-analysis of clinical trials of critically ill COVID‑19 patients.
In September 2020, the European Medicines Agency (EMA) endorsed the use of dexamethasone in adults and adolescents from twelve years of age and weighing at least 40 kilograms (88 lb) who require supplemental oxygen therapy. Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.
In November 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID‑19. Bamlanivimab is authorised for people with positive results of direct SARS-CoV-2 viral testing who are twelve years of age and older weighing at least 40 kilograms (88 lb), and who are at high risk for progressing to severe COVID‑19 or hospitalisation. This includes those who are 65 years of age or older, or who have chronic medical conditions.
In February 2021, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID‑19 in people twelve years of age or older weighing at least 40 kilograms (88 lb) who test positive for SARS‑CoV‑2 and who are at high risk for progressing to severe COVID‑19. The authorised use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions.
In April 2021, the FDA revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID‑19 in adults and certain paediatric patients.
A cytokine storm can be a complication in the later stages of severe COVID‑19. A cytokine storm is a potentially deadly immune reaction where a large amount of pro-inflammatory cytokines and chemokines are released too quickly. A cytokine storm can lead to ARDS and multiple organ failure. Data collected from Jin Yin-tan Hospital in Wuhan, China indicates that patients who had more severe responses to COVID‑19 had greater amounts of pro-inflammatory cytokines and chemokines in their system than patients who had milder responses. These high levels of pro-inflammatory cytokines and chemokines indicate presence of a cytokine storm.
Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed. It is undergoing a Phase II non-randomised trial at the national level in Italy after showing positive results in people with severe disease. Combined with a serum ferritin blood test to identify a cytokine storm (also called cytokine storm syndrome, not to be confused with cytokine release syndrome), it is meant to counter such developments, which are thought to be the cause of death in some affected people. The interleukin-6 receptor (IL-6R) antagonist was approved by the FDA to undergo a Phase III clinical trial assessing its effectiveness on COVID‑19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017. There is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood–brain barrier, and exacerbating neurotoxicity while having no effect on the incidence of CRS.
Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting T cells in hospitalised patients with COVID‑19.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID‑19 to people who need them is being investigated as a non-vaccine method of passive immunisation. Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2. The spike protein of SARS-CoV-2 is the primary target for neutralising antibodies. As of 8 August 2020, eight neutralising antibodies targeting the spike protein of SARS-CoV-2 have entered clinical studies. It has been proposed that selection of broad-neutralising antibodies against SARS-CoV-2 and SARS-CoV might be useful for treating not only COVID‑19 but also future SARS-related CoV infections. Other mechanisms, however, such as antibody-dependant cellular cytotoxicity or phagocytosis, may be possible. Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
The use of passive antibodies to treat people with active COVID‑19 is also being studied. This involves the production of convalescent serum, which consists of the liquid portion of the blood from people who recovered from the infection and contains antibodies specific to this virus, which is then administered to active patients. This strategy was tried for SARS with inconclusive results. An updated Cochrane review in May 2021 found high certainty evidence that, for the treatment of people with moderate to severe COVID‑19, convalescent plasma did not reduce mortality or bring about symptom improvement. There continues to be uncertainty about the safety of convalescent plasma administration to people with COVID‑19 and differing outcomes measured in different studies limits their use in determining efficacy.
Since the outbreak of the COVID‑19 pandemic, scholars have explored the bioethics, normative economics, and political theories of healthcare policies related to the public health crisis. Academics have pointed to the moral distress of healthcare workers, ethics of distributing scarce healthcare resources such as ventilators, and the global justice of vaccine diplomacies. The socio-economic inequalities between genders, races, groups with disabilities, communities, regions, countries, and continents have also drawn attention in academia and the general public.
Discover more about Research related topics
Effects on other diseases
The use of social distancing and the wearing of surgical masks and similar precautions against COVID‑19 may have caused a drop in the spread of the common cold and the flu.
Discover more about Effects on other diseases related topics
Source: "COVID-19", Wikipedia, Wikimedia Foundation, (2023, March 27th), https://en.wikipedia.org/wiki/COVID-19.
Get our FREE extension now!
Human coronavirus NL63
COVID-19 drug repurposing research
Timeline of the COVID-19 pandemic in 2019
Symptoms of COVID-19
Multisystem inflammatory syndrome in children
Impact of the COVID-19 pandemic on other health issues
Source control (respiratory disease)
Transmission of COVID-19
Impact of the COVID-19 pandemic on neurological, psychological and other mental health outcomes
- Coronavirus diseases, a group of closely related syndromes
- Disease X, a WHO term
- Law of declining virulence – Disproved hypothesis of epidemiologist Theobald Smith
- Theory of virulence – Theory by biologist Paul W. Ewald
- ^ "Covid-19". Oxford English Dictionary (Online ed.). Oxford University Press. April 2020. Retrieved 15 April 2020. (Subscription or participating institution membership required.)
- ^ "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 13 May 2020. Archived from the original on 17 June 2020. Retrieved 18 June 2020.
- ^ "Q&A on coronaviruses (COVID-19)". World Health Organization (WHO). 17 April 2020. Archived from the original on 14 May 2020. Retrieved 14 May 2020.
- ^ a b c "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 10 March 2023.
- ^ Page J, Hinshaw D, McKay B (26 February 2021). "In Hunt for Covid-19 Origin, Patient Zero Points to Second Wuhan Market – The man with the first confirmed infection of the new coronavirus told the WHO team that his parents had shopped there". The Wall Street Journal. Retrieved 27 February 2021.
- ^ Islam MA (April 2021). "Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients". PLOS ONE. 16 (4): e0249788. Bibcode:2021PLoSO..1649788I. doi:10.1371/journal.pone.0249788. PMC 8023501. PMID 33822812.
- ^ Islam MA (November 2020). "Prevalence of Headache in Patients With Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of 14,275 Patients". Frontiers in Neurology. 11: 562634. doi:10.3389/fneur.2020.562634. PMC 7728918. PMID 33329305.
- ^ Saniasiaya J, Islam MA (April 2021). "Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients". The Laryngoscope. 131 (4): 865–878. doi:10.1002/lary.29286. ISSN 0023-852X. PMC 7753439. PMID 33219539.
- ^ Saniasiaya J, Islam MA (November 2020). "Prevalence and Characteristics of Taste Disorders in Cases of COVID-19: A Meta-analysis of 29,349 Patients". Otolaryngology–Head and Neck Surgery. 165 (1): 33–42. doi:10.1177/0194599820981018. PMID 33320033. S2CID 229174644.
- ^ Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R (August 2020). "Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis". Mayo Clin. Proc. 95 (8): 1621–1631. doi:10.1016/j.mayocp.2020.05.030. PMC 7275152. PMID 32753137.
- ^ Oran DP, Topol EJ (January 2021). "The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review". Annals of Internal Medicine. 174 (5): M20-6976. doi:10.7326/M20-6976. PMC 7839426. PMID 33481642.
- ^ "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 6 April 2020. Archived from the original on 2 March 2020. Retrieved 19 April 2020.
- ^ a b CDC (11 February 2020). "Post-COVID Conditions". U.S. Centers for Disease Control and Prevention (CDC). Retrieved 12 July 2021.
- ^ CDC (11 February 2020). "Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). Retrieved 6 December 2020.
- ^ "Clinical Questions about COVID-19: Questions and Answers". U.S. Centers for Disease Control and Prevention (CDC). 17 November 2021. Retrieved 25 January 2022.
- ^ a b c "Overview of Testing for SARS-CoV-2, the virus that causes COVID-19". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 31 July 2022.
- ^ a b c "Nucleic Acid Amplification Tests (NAATs)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 31 July 2022.
- ^ Gorzalski AJ, Tian H, Laverdure C, Morzunov S, Verma SC, VanHooser S, et al. (August 2020). "High-Throughput Transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2". Journal of Clinical Virology. 129: 104501. doi:10.1016/j.jcv.2020.104501. PMC 7286273. PMID 32619959.
- ^ a b c d e Li C, Zhao C, Bao J, Tang B, Wang Y, Gu B (November 2020). "Laboratory diagnosis of coronavirus disease-2019 (COVID-19)". Clinica Chimica Acta; International Journal of Clinical Chemistry. 510: 35–46. doi:10.1016/j.cca.2020.06.045. PMC 7329657. PMID 32621814.
- ^ "2nd U.S. Case Of Wuhan Coronavirus Confirmed". NPR. Retrieved 4 April 2020.
- ^ McNeil Jr DG (2 February 2020). "Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say". The New York Times. ISSN 0362-4331. Archived from the original on 2 February 2020. Retrieved 4 April 2020.
- ^ Griffiths J. "Wuhan coronavirus deaths spike again as outbreak shows no signs of slowing". CNN. Retrieved 4 April 2020.
- ^ Jiang S, Xia S, Ying T, Lu L (May 2020). "A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome". Cellular & Molecular Immunology. 17 (5): 554. doi:10.1038/s41423-020-0372-4. PMC 7091741. PMID 32024976.
- ^ Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. (February 2020). "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster". Lancet. 395 (10223): 514–523. doi:10.1016/S0140-6736(20)30154-9. PMC 7159286. PMID 31986261.
- ^ Shablovsky S (September 2017). "The legacy of the Spanish flu". Science. 357 (6357): 1245. Bibcode:2017Sci...357.1245S. doi:10.1126/science.aao4093. ISSN 0036-8075. S2CID 44116811.
- ^ "Stop the coronavirus stigma now". Nature. 580 (7802): 165. 7 April 2020. Bibcode:2020Natur.580..165.. doi:10.1038/d41586-020-01009-0. PMID 32265571. S2CID 214809950. Retrieved 16 April 2020.
- ^ "Novel Coronavirus (2019-nCoV) Situation Report – 1" (PDF). World Health Organization (WHO). 21 January 2020.
- ^ "Novel Coronavirus(2019-nCoV) Situation Report – 10" (PDF). World Health Organization (WHO). 30 January 2020.
- ^ "Novel coronavirus named 'Covid-19': WHO". Today. Singapore. Archived from the original on 21 March 2020. Retrieved 11 February 2020.
- ^ "The coronavirus spreads racism against – and among – ethnic Chinese". The Economist. 17 February 2020. Archived from the original on 17 February 2020. Retrieved 17 February 2020.
- ^ World Health Organization Best Practices for the Naming of New Human Infectious Diseases (PDF) (Report). World Health Organization (WHO). May 2015. hdl:10665/163636.
- ^ a b "Naming the coronavirus disease (COVID-19) and the virus that causes it". World Health Organization (WHO). Archived from the original on 28 February 2020. Retrieved 13 March 2020.
- ^ "Novel Coronavirus(2019-nCoV) Situation Report – 22" (PDF). WHO. 11 February 2020.
- ^ Gover AR, Harper SB, Langton L (July 2020). "Anti-Asian Hate Crime During the COVID-19 Pandemic: Exploring the Reproduction of Inequality". American Journal of Criminal Justice. 45 (4): 647–667. doi:10.1007/s12103-020-09545-1. PMC 7364747. PMID 32837171.
- ^ "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 22 February 2021. Archived from the original on 4 March 2021. Retrieved 4 March 2021.
- ^ Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade RG (23 June 2020). "The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries". PLOS ONE. 15 (6): e0234765. Bibcode:2020PLoSO..1534765G. doi:10.1371/journal.pone.0234765. PMC 7310678. PMID 32574165. S2CID 220046286.
- ^ Pardhan S, Vaughan M, Zhang J, Smith L, Chichger H (1 November 2020). "Sore eyes as the most significant ocular symptom experienced by people with COVID-19: a comparison between pre-COVID-19 and during COVID-19 states". BMJ Open Ophthalmology. 5 (1): e000632. doi:10.1136/bmjophth-2020-000632. PMC 7705420. PMID 34192153.
- ^ "COVID toes, rashes: How the coronavirus can affect your skin". www.aad.org. Retrieved 20 March 2022.
- ^ a b "Clinical characteristics of COVID-19". European Centre for Disease Prevention and Control. Retrieved 29 December 2020.
- ^ Paderno A, Mattavelli D, Rampinelli V, Grammatica A, Raffetti E, Tomasoni M, et al. (December 2020). "Olfactory and Gustatory Outcomes in COVID-19: A Prospective Evaluation in Nonhospitalized Subjects". Otolaryngology–Head and Neck Surgery. 163 (6): 1144–1149. doi:10.1177/0194599820939538. PMC 7331108. PMID 32600175.
- ^ Chabot AB, Huntwork MP (September 2021). "Turmeric as a Possible Treatment for COVID-19-Induced Anosmia and Ageusia". Cureus. 13 (9): e17829. doi:10.7759/cureus.17829. PMC 8502749. PMID 34660038.
- ^ Niazkar HR, Zibaee B, Nasimi A, Bahri N (July 2020). "The neurological manifestations of COVID-19: a review article". Neurological Sciences. 41 (7): 1667–1671. doi:10.1007/s10072-020-04486-3. PMC 7262683. PMID 32483687.
- ^ "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 6 April 2020. Archived from the original on 2 March 2020. Retrieved 19 April 2020.
- ^ Multiple sources:
- Oran DP, Topol EJ (May 2021). "The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review". Annals of Internal Medicine. 174 (5): 655–662. doi:10.7326/M20-6976. PMC 7839426. PMID 33481642.
- "Transmission of COVID-19". European Centre for Disease Prevention and Control. Retrieved 6 December 2020.
- Nogrady B (November 2020). "What the data say about asymptomatic COVID infections". Nature. 587 (7835): 534–535. Bibcode:2020Natur.587..534N. doi:10.1038/d41586-020-03141-3. PMID 33214725.
- ^ a b Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, Ma K (February 2021). "A systematic review of asymptomatic infections with COVID-19". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. 54 (1): 12–16. doi:10.1016/j.jmii.2020.05.001. PMC 7227597. PMID 32425996.
- ^ Oran DP, Topol EJ (September 2020). "Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review". Annals of Internal Medicine. 173 (5): 362–367. doi:10.7326/M20-3012. PMC 7281624. PMID 32491919.
- ^ Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. (June 2020). "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. 53 (3): 404–412. doi:10.1016/j.jmii.2020.02.012. PMC 7128959. PMID 32173241.
- ^ a b Furukawa NW, Brooks JT, Sobel J (July 2020). "Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic". Emerging Infectious Diseases. 26 (7). doi:10.3201/eid2607.201595. PMC 7323549. PMID 32364890.
- ^ a b Gandhi RT, Lynch JB, Del Rio C (October 2020). "Mild or Moderate Covid-19". The New England Journal of Medicine. 383 (18): 1757–1766. doi:10.1056/NEJMcp2009249. PMID 32329974.
- ^ Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. (August 2020). "Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases". BMJ Open. 10 (8): e039856. doi:10.1136/bmjopen-2020-039856. PMC 7409948. PMID 32759252.
- ^ Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (August 2020). "Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 324 (8): 782–793. doi:10.1001/jama.2020.12839. PMID 32648899. S2CID 220465311.
- ^ "Half of young adults with COVID-19 had persistent symptoms after 6 months". medicalxpress.com. Retrieved 10 July 2021.
- ^ Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. (September 2021). "Long COVID in a prospective cohort of home-isolated patients". Nature Medicine. 27 (9): 1607–1613. doi:10.1038/s41591-021-01433-3. PMC 8440190. PMID 34163090. S2CID 235625772.
- ^ CDC (1 September 2022). "Post-COVID Conditions". Centers for Disease Control and Prevention. Retrieved 21 September 2022.
- ^ CDC (11 February 2020). "COVID-19 and Your Health". Centers for Disease Control and Prevention. Retrieved 23 January 2021.
- ^ CDC (29 March 2022). "Omicron Variant: What You Need to Know". Centers for Disease Control and Prevention. Retrieved 15 June 2022.
- ^ Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. (February 2020). "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China". International Journal of Infectious Diseases. 91: 264–266. doi:10.1016/j.ijid.2020.01.009. PMC 7128332. PMID 31953166.
- ^ Murthy S, Gomersall CD, Fowler RA (April 2020). "Care for Critically Ill Patients With COVID-19". JAMA. 323 (15): 1499–1500. doi:10.1001/jama.2020.3633. PMID 32159735.
- ^ Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32150360. Retrieved 18 March 2020.
- ^ Heymann DL, Shindo N, et al. (WHO Scientific and Technical Advisory Group for Infectious Hazards) (February 2020). "COVID-19: what is next for public health?". Lancet. 395 (10224): 542–545. doi:10.1016/s0140-6736(20)30374-3. PMC 7138015. PMID 32061313.
- ^ Romiti GF, Corica B, Lip GY, Proietti M (June 2021). "Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis". Journal of Clinical Medicine. 10 (11): 2490. doi:10.3390/jcm10112490. PMC 8200114. PMID 34199857.
- ^ Wen W, Zhang H, Zhou M, Cheng Y, Ye L, Chen J, et al. (November 2020). "Arrhythmia in patients with severe coronavirus disease (COVID-19): a meta-analysis". European Review for Medical and Pharmacological Sciences. 24 (21): 11395–11401. doi:10.26355/eurrev_202011_23632. PMID 33215461. S2CID 227077132.
- ^ Long B, Brady WJ, Koyfman A, Gottlieb M (July 2020). "Cardiovascular complications in COVID-19". The American Journal of Emergency Medicine. 38 (7): 1504–1507. doi:10.1016/j.ajem.2020.04.048. PMC 7165109. PMID 32317203.
- ^ Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. (November 2020). "Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)". JAMA Cardiology. 5 (11): 1265–1273. doi:10.1001/jamacardio.2020.3557. PMC 7385689. PMID 32730619.
- ^ Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. (November 2020). "Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases". JAMA Cardiology. 5 (11): 1281–1285. doi:10.1001/jamacardio.2020.3551. PMC 7385672. PMID 32730555.
- ^ Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, et al. (September 2020). "Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management". Heart Rhythm. 17 (9): 1463–1471. doi:10.1016/j.hrthm.2020.05.001. PMC 7199677. PMID 32387246.
- ^ Xu L, Liu J, Lu M, Yang D, Zheng X (May 2020). "Liver injury during highly pathogenic human coronavirus infections". Liver International. 40 (5): 998–1004. doi:10.1111/liv.14435. PMC 7228361. PMID 32170806.
- ^ a b c Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (May 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 323 (18): 1824–1836. doi:10.1001/jama.2020.6019. PMID 32282022.
- ^ Carod-Artal FJ (May 2020). "Neurological complications of coronavirus and COVID-19". Revista de Neurología. 70 (9): 311–322. doi:10.33588/rn.7009.2020179. PMID 32329044. S2CID 226200547.
- ^ Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. (June 2020). "Guillain-Barré Syndrome Associated with SARS-CoV-2". The New England Journal of Medicine. 382 (26): 2574–2576. doi:10.1056/NEJMc2009191. PMC 7182017. PMID 32302082.
- ^ "Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19". World Health Organization (WHO). 15 May 2020. Retrieved 20 May 2020.
- ^ HAN Archive – 00432. U.S. Centers for Disease Control and Prevention (CDC) (Report). 15 May 2020. Retrieved 20 May 2020.
- ^ Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B (August 2020). "COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features". Radiology. 296 (2): E119–E120. doi:10.1148/radiol.2020201187. PMC 7233386. PMID 32228363.
- ^ a b Córdoba-Vives S, Peñaranda G (April 2020). "COVID-19 y Embarazo". Medical Journal of Costa Rica (in Spanish): 629. Archived from the original on 18 June 2021. Retrieved 14 February 2022.
- ^ Das S, Dhar S (July 2021). "Mucormycosis Following COVID-19 Infections: an Insight". The Indian Journal of Surgery. 84 (3): 585–586. doi:10.1007/s12262-021-03028-1. PMC 8270771. PMID 34276145. S2CID 235782159.
- ^ Baruah C, Devi P, Deka B, Sharma DK (June 2021). "Mucormycosis and Aspergillosis have been Linked to Covid-19-Related Fungal Infections in India". Advancements in Case Studies. 3 (1). doi:10.31031/AICS.2021.03.000555. ISSN 2639-0531. S2CID 244678882 – via ResearchGate.
- ^ Hu B, Guo H, Zhou P, Shi ZL (March 2021). "Characteristics of SARS-CoV-2 and COVID-19". Nature Reviews. Microbiology. 19 (3): 141–154. doi:10.1038/s41579-020-00459-7. PMC 7537588. PMID 33024307.
- ^ a b Wang CC, Prather KA, Sznitman J, Jimenez JL, Lakdawala SS, Tufekci Z, Marr LC (August 2021). "Airborne transmission of respiratory viruses". Science. 373 (6558). Bibcode:2021Sci...373.....W. doi:10.1126/science.abd9149. PMC 8721651. PMID 34446582.
- ^ Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R (May 2021). "Ten scientific reasons in support of airborne transmission of SARS-CoV-2". Lancet. 397 (10285): 1603–1605. doi:10.1016/s0140-6736(21)00869-2. PMC 8049599. PMID 33865497.
- ^ Bourouiba L (13 July 2021). "Fluid Dynamics of Respiratory Infectious Diseases". Annual Review of Biomedical Engineering. 23 (1): 547–577. doi:10.1146/annurev-bioeng-111820-025044. hdl:1721.1/131115. PMID 34255991. S2CID 235823756. Retrieved 7 September 2021.
- ^ Stadnytskyi, Valentyn; Bax, Christina E.; Bax, Adriaan; Anfinrud, Philip (2 June 2020). "The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission". Proceedings of the National Academy of Sciences. 117 (22): 11875–11877. Bibcode:2020PNAS..11711875S. doi:10.1073/pnas.2006874117. PMC 7275719. PMID 32404416.
- ^ Miller SL, Nazaroff WW, Jimenez JL, Boerstra A, Buonanno G, Dancer SJ, et al. (March 2021). "Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event". Indoor Air. 31 (2): 314–323. doi:10.1111/ina.12751. PMC 7537089. PMID 32979298.
- ^ He, Xi; Lau, Eric H. Y.; Wu, Peng; Deng, Xilong; Wang, Jian; Hao, Xinxin; Lau, Yiu Chung; Wong, Jessica Y.; Guan, Yujuan; Tan, Xinghua; Mo, Xiaoneng; Chen, Yanqing; Liao, Baolin; Chen, Weilie; Hu, Fengyu; Zhang, Qing; Zhong, Mingqiu; Wu, Yanrong; Zhao, Lingzhai; Zhang, Fuchun; Cowling, Benjamin J.; Li, Fang; Leung, Gabriel M. (September 2020). "Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19". Nature Medicine. 26 (9): 1491–1493. doi:10.1038/s41591-020-1016-z. PMC 7413015. PMID 32770170. S2CID 221050261.
- ^ a b c d Communicable Diseases Network Australia. "Coronavirus Disease 2019 (COVID-19): CDNA National Guidelines for Public Health Units". 5.1. Communicable Diseases Network Australia/Australian Government Department of Health.
- ^ "Clinical Questions about COVID-19: Questions and Answers". Centers for Disease Control and Prevention. 4 March 2021.
- ^ "Scientific Brief: SARS-CoV-2 Transmission". Centers for Disease Control and Prevention. 7 May 2021. Retrieved 8 May 2021.
- ^ "Coronavirus disease (COVID-19): How is it transmitted?". World Health Organization. 30 April 2021.
- ^ a b c d e • "COVID-19: epidemiology, virology and clinical features". GOV.UK. Retrieved 18 October 2020.
• Communicable Diseases Network Australia. "Coronavirus Disease 2019 (COVID-19) - CDNA Guidelines for Public Health Units". Version 4.4. Australian Government Department of Health. Retrieved 17 May 2021.
• Public Health Agency of Canada (3 November 2020). "COVID-19: Main modes of transmission". aem. Retrieved 18 May 2021.
• "Transmission of COVID-19". European Centre for Disease Prevention and Control. Retrieved 18 May 2021.
• Meyerowitz EA, Richterman A, Gandhi RT, Sax PE (January 2021). "Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors". Annals of Internal Medicine. 174 (1): 69–79. doi:10.7326/M20-5008. ISSN 0003-4819. PMC 7505025. PMID 32941052.
- ^ a b c Tang JW, Marr LC, Li Y, Dancer SJ (April 2021). "Covid-19 has redefined airborne transmission". BMJ. 373: n913. doi:10.1136/bmj.n913. PMID 33853842.
- ^ a b Morawska L, Allen J, Bahnfleth W, Bluyssen PM, Boerstra A, Buonanno G, et al. (May 2021). "A paradigm shift to combat indoor respiratory infection" (PDF). Science. 372 (6543): 689–691. Bibcode:2021Sci...372..689M. doi:10.1126/science.abg2025. PMID 33986171. S2CID 234487289.
- ^ Biswas Riddhideep; Pal Anish; Pal Ritam; Sarkar Sourav; Mukhopadhyay Achintya (2022). "Risk assessment of COVID infection by respiratory droplets from cough for various ventilation scenarios inside an elevator: An OpenFOAM-based computational fluid dynamics analysis". Physics of Fluids. 34 (1): 013318. arXiv:2109.12841. Bibcode:2022PhFl...34a3318B. doi:10.1063/5.0073694. PMID 35340680. S2CID 245828044.
- ^ a b Meyerowitz EA, Richterman A, Gandhi RT, Sax PE (January 2021). "Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors". Annals of Internal Medicine. 174 (1): 69–79. doi:10.7326/M20-5008. ISSN 0003-4819. PMC 7505025. PMID 32941052.
- ^ CDC (11 February 2020). "Healthcare Workers". Centers for Disease Control and Prevention. Retrieved 29 March 2022.
- ^ Liu T, Gong D, Xiao J, Hu J, He G, Rong Z, Ma W (October 2020). "Cluster infections play important roles in the rapid evolution of COVID-19 transmission: A systematic review". International Journal of Infectious Diseases. 99: 374–380. doi:10.1016/j.ijid.2020.07.073. PMC 7405860. PMID 32768702.
- ^ "Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China – fourth update" (PDF). European Centre for Disease Prevention and Control. 14 February 2020. Retrieved 8 March 2020.
- ^ a b Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (April 2020). "The proximal origin of SARS-CoV-2". Nature Medicine. 26 (4): 450–452. doi:10.1038/s41591-020-0820-9. PMC 7095063. PMID 32284615.
- ^ Zhou, Peng; Yang, Xing-Lou; Wang, Xian-Guang; Hu, Ben; Zhang, Lei; Zhang, Wei; Si, Hao-Rui; Zhu, Yan; Li, Bei; Huang, Chao-Lin; Chen, Hui-Dong; Chen, Jing; Luo, Yun; Guo, Hua; Jiang, Ren-Di; Liu, Mei-Qin; Chen, Ying; Shen, Xu-Rui; Wang, Xi; Zheng, Xiao-Shuang; Zhao, Kai; Chen, Quan-Jiao; Deng, Fei; Liu, Lin-Lin; Yan, Bing; Zhan, Fa-Xian; Wang, Yan-Yi; Xiao, Geng-Fu; Shi, Zheng-Li (2020). "A pneumonia outbreak associated with a new coronavirus of probable bat origin". Nature. 579 (7798): 270–273. Bibcode:2020Natur.579..270Z. doi:10.1038/s41586-020-2012-7. PMC 7095418. PMID 32015507.
- ^ Gibbens S (18 March 2020). "Why soap is preferable to bleach in the fight against coronavirus". National Geographic. Archived from the original on 2 April 2020. Retrieved 2 April 2020.
- ^ Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. (February 2020). "A Novel Coronavirus from Patients with Pneumonia in China, 2019". The New England Journal of Medicine. 382 (8): 727–733. doi:10.1056/NEJMoa2001017. PMC 7092803. PMID 31978945.
- ^ a b c Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (PDF) (Report). World Health Organization (WHO). February 2020. Archived (PDF) from the original on 29 February 2020. Retrieved 21 March 2020.
- ^ "Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)". World Health Organization (WHO). Retrieved 25 January 2022.
- ^ Rathore JS, Ghosh C (August 2020). "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview". Pathogens and Disease. 78 (6). doi:10.1093/femspd/ftaa042. OCLC 823140442. PMC 7499575. PMID 32840560.
- ^ Thomas S (October 2020). "The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET". Pathogens & Immunity. 5 (1): 342–363. doi:10.20411/pai.v5i1.377. PMC 7608487. PMID 33154981.
- ^ Koyama T, Platt D, Parida L (July 2020). "Variant analysis of SARS-CoV-2 genomes". Bulletin of the World Health Organization. 98 (7): 495–504. doi:10.2471/BLT.20.253591. PMC 7375210. PMID 32742035.
We detected in total 65776 variants with 5775 distinct variants.
- ^ a b Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. (November 2020). "A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology". Nature Microbiology. 5 (11): 1403–1407. doi:10.1038/s41564-020-0770-5. PMC 7610519. PMID 32669681.
- ^ "Tracking SARS-CoV-2 variants". World Health Organization. 1 July 2021. Retrieved 5 July 2021.
- ^ Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, et al. (August 2020). "Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020". Euro Surveillance. 25 (32). doi:10.2807/1560-7917.ES.2020.25.32.2001410. PMC 7427299. PMID 32794443.
- ^ "PANGO lineages". cov-lineages.org. Archived from the original on 10 May 2021. Retrieved 9 May 2021.
- ^ Lauring AS, Hodcroft EB (February 2021). "Genetic Variants of SARS-CoV-2-What Do They Mean?". JAMA. 325 (6): 529–531. doi:10.1001/jama.2020.27124. PMID 33404586. S2CID 230783233.
- ^ Abdool Karim SS, de Oliveira T (May 2021). "New SARS-CoV-2 Variants – Clinical, Public Health, and Vaccine Implications". The New England Journal of Medicine. Massachusetts Medical Society. 384 (19): 1866–1868. doi:10.1056/nejmc2100362. ISSN 0028-4793. PMC 8008749. PMID 33761203.
- ^ Mallapaty S (November 2020). "COVID mink analysis shows mutations are not dangerous – yet". Nature. 587 (7834): 340–341. Bibcode:2020Natur.587..340M. doi:10.1038/d41586-020-03218-z. PMID 33188367. S2CID 226947606.
- ^ Larsen HD, Fonager J, Lomholt FK, Dalby T, Benedetti G, Kristensen B, et al. (February 2021). "Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020". Euro Surveillance. 26 (5): 2100009. doi:10.2807/1560-7917.ES.2021.26.5.210009. PMC 7863232. PMID 33541485.
As at 1 February 2021, we assess that the cluster 5 variant is no longer circulating among humans in Denmark.
- ^ "New COVID-19 Variants". U.S. Centers for Disease Control and Prevention (CDC). 28 June 2021 [First published 11 February 2020]. Retrieved 15 July 2021.
- ^ "COVID-19 Weekly Epidemiological Update Edition 69". World Health Organization (WHO). 7 December 2021.
- ^ "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern". World Health Organization (WHO). Retrieved 9 December 2021.
- ^ Harrison AG, Lin T, Wang P (December 2020). "Mechanisms of SARS-CoV-2 Transmission and Pathogenesis". Trends in Immunology. 41 (12): 1100–1115. doi:10.1016/j.it.2020.10.004. PMC 7556779. PMID 33132005.
- ^ Verdecchia P, Cavallini C, Spanevello A, Angeli F (June 2020). "The pivotal link between ACE2 deficiency and SARS-CoV-2 infection". European Journal of Internal Medicine. 76: 14–20. doi:10.1016/j.ejim.2020.04.037. PMC 7167588. PMID 32336612.
- ^ Letko M, Marzi A, Munster V (April 2020). "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses". Nature Microbiology. 5 (4): 562–569. doi:10.1038/s41564-020-0688-y. PMC 7095430. PMID 32094589.
- ^ Marik PE, Iglesias J, Varon J, Kory P (January 2021). "A scoping review of the pathophysiology of COVID-19". International Journal of Immunopathology and Pharmacology. 35: 20587384211048026. doi:10.1177/20587384211048026. PMC 8477699. PMID 34569339.
- ^ a b Meunier N, Briand L, Jacquin-Piques A, Brondel L, Pénicaud L (June 2020). "COVID 19-Induced Smell and Taste Impairments: Putative Impact on Physiology". Frontiers in Physiology. 11: 625110. doi:10.3389/fphys.2020.625110. PMC 7870487. PMID 33574768.
- ^ Guerrero JI, Barragán LA, Martínez JD, Montoya JP, Peña A, Sobrino FE, et al. (June 2021). "Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings". BMC Infectious Diseases. 21 (1): 515. doi:10.1186/s12879-021-06185-6. PMC 8170436. PMID 34078305.
- ^ a b Pezzini A, Padovani A (November 2020). "Lifting the mask on neurological manifestations of COVID-19". Nature Reviews. Neurology. 16 (11): 636–644. doi:10.1038/s41582-020-0398-3. PMC 7444680. PMID 32839585.
- ^ Li YC, Bai WZ, Hashikawa T (June 2020). "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients". Journal of Medical Virology. 92 (6): 552–555. doi:10.1002/jmv.25728. PMC 7228394. PMID 32104915.
- ^ Baig AM, Khaleeq A, Ali U, Syeda H (April 2020). "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms". ACS Chemical Neuroscience. 11 (7): 995–998. doi:10.1021/acschemneuro.0c00122. PMC 7094171. PMID 32167747.
- ^ Yavarpour-Bali H, Ghasemi-Kasman M (September 2020). "Update on neurological manifestations of COVID-19". Life Sciences. 257: 118063. doi:10.1016/j.lfs.2020.118063. PMC 7346808. PMID 32652139.
- ^ Covid can shrink brain and damage its tissue, finds research The Guardian
- ^ Scans reveal how Covid may change the brain BBC
- ^ "Even mild Covid is linked to brain damage months after illness, scans show". NBC News.
- ^ Gu J, Han B, Wang J (May 2020). "COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission". Gastroenterology. 158 (6): 1518–1519. doi:10.1053/j.gastro.2020.02.054. PMC 7130192. PMID 32142785.
- ^ Mönkemüller K, Fry L, Rickes S (May 2020). "COVID-19, coronavirus, SARS-CoV-2 and the small bowel". Revista Espanola de Enfermedades Digestivas. 112 (5): 383–388. doi:10.17235/reed.2020.7137/2020. PMID 32343593. S2CID 216645754.
- ^ Almamlouk R, Kashour T, Obeidat S, Bois MC, Maleszewski JJ, Omrani OA, et al. (August 2022). "COVID-19-Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review". Clinical Microbiology and Infection. 28 (8): 1066–1075. doi:10.1016/j.cmi.2022.03.021. PMC 8941843. PMID 35339672.
- ^ a b c Zheng YY, Ma YT, Zhang JY, Xie X (May 2020). "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology. 17 (5): 259–260. doi:10.1038/s41569-020-0360-5. PMC 7095524. PMID 32139904.
- ^ a b c Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (February 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. PMC 7159299. PMID 31986264.
- ^ "Coronavirus disease 2019 (COVID-19): Myocardial infarction and other coronary artery disease issues". UpToDate. Retrieved 28 September 2020.
- ^ Turner AJ, Hiscox JA, Hooper NM (June 2004). "ACE2: from vasopeptidase to SARS virus receptor". Trends in Pharmacological Sciences. 25 (6): 291–4. doi:10.1016/j.tips.2004.04.001. PMC 7119032. PMID 15165741.
- ^ Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L (October 2020). "The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management". Thrombosis Research. Elsevier BV. 194: 101–115. doi:10.1016/j.thromres.2020.06.029. PMC 7305763. PMID 32788101.
- ^ a b c Wadman M (April 2020). "How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes". Science. doi:10.1126/science.abc3208.
- ^ "NIH study uncovers blood vessel damage and inflammation in COVID-19 patients' brains but no infection". National Institutes of Health (NIH). 30 December 2020. Retrieved 17 January 2021.
- ^ Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, et al. (February 2021). "Microvascular Injury in the Brains of Patients with Covid-19". The New England Journal of Medicine. 384 (5): 481–483. doi:10.1056/nejmc2033369. PMC 7787217. PMID 33378608.
- ^ Kubánková M, Hohberger B, Hoffmanns J, Fürst J, Herrmann M, Guck J, et al. (July 2021). "Physical phenotype of blood cells is altered in COVID-19". Biophysical Journal. 120 (14): 2838–2847. Bibcode:2021BpJ...120.2838K. doi:10.1016/j.bpj.2021.05.025. PMC 8169220. PMID 34087216.
- ^ Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. (July 2020). "Extrapulmonary manifestations of COVID-19". Nature Medicine. 26 (7): 1017–1032. doi:10.1038/s41591-020-0968-3. PMID 32651579. S2CID 220462000.
- ^ "Coronavirus: Kidney Damage Caused by COVID-19". Johns Hopkins Medicine. 14 May 2020. Retrieved 25 January 2022.
- ^ a b c d e f g h Eketunde AO, Mellacheruvu SP, Oreoluwa P (July 2020). "A Review of Postmortem Findings in Patients With COVID-19". Cureus. Cureus, Inc. 12 (7): e9438. doi:10.7759/cureus.9438. PMC 7451084. PMID 32864262. S2CID 221352704.
- ^ Ziegler, CGK; Allon, SJ; Nyquist, SK; Mbano, IM; Miao, VN; Tzouanas, CN; Cao, Y; Yousif, AS; Bals, J; Hauser, BM; Feldman, J; Muus, C; Wadsworth MH, 2nd; Kazer, SW; Hughes, TK; Doran, B; Gatter, GJ; Vukovic, M; Taliaferro, F; Mead, BE; Guo, Z; Wang, JP; Gras, D; Plaisant, M; Ansari, M; Angelidis, I; Adler, H; Sucre, JMS; Taylor, CJ; Lin, B; Waghray, A; Mitsialis, V; Dwyer, DF; Buchheit, KM; Boyce, JA; Barrett, NA; Laidlaw, TM; Carroll, SL; Colonna, L; Tkachev, V; Peterson, CW; Yu, A; Zheng, HB; Gideon, HP; Winchell, CG; Lin, PL; Bingle, CD; Snapper, SB; Kropski, JA; Theis, FJ; Schiller, HB; Zaragosi, LE; Barbry, P; Leslie, A; Kiem, HP; Flynn, JL; Fortune, SM; Berger, B; Finberg, RW; Kean, LS; Garber, M; Schmidt, AG; Lingwood, D; Shalek, AK; Ordovas-Montanes, J; HCA Lung Biological Network. Electronic address, [email protected]; HCA Lung Biological, Network. (28 May 2020). "SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues". Cell. 181 (5): 1016–1035.e19. doi:10.1016/j.cell.2020.04.035. PMC 7252096. PMID 32413319.
- ^ Sajuthi, SP; DeFord, P; Li, Y; Jackson, ND; Montgomery, MT; Everman, JL; Rios, CL; Pruesse, E; Nolin, JD; Plender, EG; Wechsler, ME; Mak, ACY; Eng, C; Salazar, S; Medina, V; Wohlford, EM; Huntsman, S; Nickerson, DA; Germer, S; Zody, MC; Abecasis, G; Kang, HM; Rice, KM; Kumar, R; Oh, S; Rodriguez-Santana, J; Burchard, EG; Seibold, MA (12 October 2020). "Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium". Nature Communications. 11 (1): 5139. Bibcode:2020NatCo..11.5139S. doi:10.1038/s41467-020-18781-2. PMC 7550582. PMID 33046696.
- ^ Tretter, F; Peters, EMJ; Sturmberg, J; Bennett, J; Voit, E; Dietrich, JW; Smith, G; Weckwerth, W; Grossman, Z; Wolkenhauer, O; Marcum, JA (28 September 2022). "Perspectives of (/memorandum for) systems thinking on COVID-19 pandemic and pathology". Journal of Evaluation in Clinical Practice. doi:10.1111/jep.13772. PMC 9538129. PMID 36168893. S2CID 252566067.
- ^ Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (May 2020). "Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality". International Journal of Antimicrobial Agents. 55 (5): 105954. doi:10.1016/j.ijantimicag.2020.105954. PMC 7118634. PMID 32234467.
- ^ Gómez-Rial J, Rivero-Calle I, Salas A, Martinón-Torres F (2020). "Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy". Infection and Drug Resistance. 13: 2485–2493. doi:10.2147/IDR.S258639. PMC 7383015. PMID 32801787.
- ^ Dai L, Gao GF (February 2021). "Viral targets for vaccines against COVID-19". Nature Reviews. Immunology. 21 (2): 73–82. doi:10.1038/s41577-020-00480-0. ISSN 1474-1733. PMC 7747004. PMID 33340022.
- ^ a b Boopathi S, Poma AB, Kolandaivel P (April 2020). "Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment". Journal of Biomolecular Structure & Dynamics. 39 (9): 3409–3418. doi:10.1080/07391102.2020.1758788. PMC 7196923. PMID 32306836.
- ^ Kai H, Kai M (July 2020). "Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19". Hypertension Research. 43 (7): 648–654. doi:10.1038/s41440-020-0455-8. PMC 7184165. PMID 32341442.
- ^ Chen HX, Chen ZH, Shen HH (October 2020). "[Structure of SARS-CoV-2 and treatment of COVID-19]". Sheng Li Xue Bao. 72 (5): 617–630. PMID 33106832.
- ^ Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z (4 September 2020). "Immunological considerations for COVID-19 vaccine strategies". Nature Reviews Immunology. 20 (10): 615–632. doi:10.1038/s41577-020-00434-6. ISSN 1474-1741. PMC 7472682. PMID 32887954.
- ^ Zhang Q, Ju B, Ge J, Chan JF, Cheng L, Wang R, et al. (July 2021). "Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2". Nature Communications. 12 (1): 4210. Bibcode:2021NatCo..12.4210Z. doi:10.1038/s41467-021-24514-w. PMC 8270942. PMID 34244522. S2CID 235786394.
- ^ Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S (July 2020). "Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment". Clinical Rheumatology. 39 (7): 2085–2094. doi:10.1007/s10067-020-05190-5. PMC 7260446. PMID 32474885.
- ^ Quirch M, Lee J, Rehman S (August 2020). "Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review". Journal of Medical Internet Research. 22 (8): e20193. doi:10.2196/20193. PMC 7428145. PMID 32707537.
- ^ Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. (2020). "Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper". Frontiers in Immunology. 11: 1648. doi:10.3389/fimmu.2020.01648. PMC 7365905. PMID 32754159.
- ^ a b c d e f Wastnedge EA, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA, et al. (January 2021). "Pregnancy and COVID-19". Physiological Reviews. 101 (1): 303–318. doi:10.1152/physrev.00024.2020. PMC 7686875. PMID 32969772.
- ^ Campbell D (10 October 2021). "One in six most critically ill NHS Covid patients are unvaccinated pregnant women". The Guardian. Retrieved 25 January 2022.
- ^ a b Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. (August 2020). "Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases". Radiology. 296 (2): E32–E40. doi:10.1148/radiol.2020200642. PMC 7233399. PMID 32101510.
- ^ a b c d Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (July 2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". AJR. American Journal of Roentgenology. 215 (1): 87–93. doi:10.2214/AJR.20.23034. PMID 32174129.
- ^ "2019 Novel Coronavirus (2019-nCoV) Situation Summary". U.S. Centers for Disease Control and Prevention (CDC). 30 January 2020. Archived from the original on 26 January 2020. Retrieved 30 January 2020.
- ^ "Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans". World Health Organization (WHO). Archived from the original on 15 March 2020. Retrieved 14 March 2020.
- ^ Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. (December 2020). "Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples". Clinical Infectious Diseases. 71 (10): 2663–2666. doi:10.1093/cid/ciaa638. PMC 7314198. PMID 32442256.
- ^ "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 26 March 2020.
- ^ "Real-Time RT-PCR Panel for Detection 2019-nCoV". U.S. Centers for Disease Control and Prevention (CDC). 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
- ^ "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". World Health Organization (WHO). Archived from the original on 17 March 2020. Retrieved 13 March 2020.
- ^ "NHS staff will be first to get new coronavirus antibody test, medical chief promises". The Independent. 14 May 2020. Retrieved 14 May 2020.
- ^ Heneghan C, Jefferson T (1 September 2020). "Virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR". CEBM. Retrieved 19 September 2020.
- ^ Lu J, Peng J, Xiong Q, Liu Z, Lin H, Tan X, et al. (September 2020). "Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR". EBioMedicine. 59: 102960. doi:10.1016/j.ebiom.2020.102960. PMC 7444471. PMID 32853988.
- ^ Spencer E, Jefferson T, Brassey J, Heneghan C (11 September 2020). "When is Covid, Covid?". The Centre for Evidence-Based Medicine. Retrieved 19 September 2020.
- ^ "SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence". GOV.UK. Retrieved 19 September 2020.
- ^ "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". American College of Radiology. 22 March 2020. Archived from the original on 28 March 2020.
- ^ Pormohammad A, Ghorbani S, Khatami A, Razizadeh MH, Alborzi E, Zarei M, et al. (October 2020). "Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings". Reviews in Medical Virology. 31 (3): e2179. doi:10.1002/rmv.2179. PMC 7646051. PMID 33035373. S2CID 222255245.
- ^ Lee EY, Ng MY, Khong PL (April 2020). "COVID-19 pneumonia: what has CT taught us?". The Lancet. Infectious Diseases. 20 (4): 384–385. doi:10.1016/S1473-3099(20)30134-1. PMC 7128449. PMID 32105641.
- ^ a b Li Y, Xia L (June 2020). "Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management". AJR. American Journal of Roentgenology. 214 (6): 1280–1286. doi:10.2214/AJR.20.22954. PMID 32130038. S2CID 212416282.
- ^ "COVID-19 Database". Società Italiana di Radiologia Medica e Interventistica (in Italian). Retrieved 11 March 2020.
- ^ "ICD-10 Version:2019". World Health Organization (WHO). 2019. Archived from the original on 31 March 2020. Retrieved 31 March 2020.
U07.2 – COVID-19, virus not identified – COVID-19 NOS – Use this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available. Use additional code, if desired, to identify pneumonia or other manifestations
- ^ Giani M, Seminati D, Lucchini A, Foti G, Pagni F (May 2020). "Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe". Journal of Thoracic Oncology. 15 (5): e65–e66. doi:10.1016/j.jtho.2020.03.008. PMC 7118681. PMID 32194247.
- ^ Lillicrap D (April 2020). "Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia". Journal of Thrombosis and Haemostasis. 18 (4): 786–787. doi:10.1111/jth.14781. PMC 7166410. PMID 32212240.
- ^ Mitra A, Dwyre DM, Schivo M, Thompson GR, Cohen SH, Ku N, et al. (August 2020). "Leukoerythroblastic reaction in a patient with COVID-19 infection". American Journal of Hematology. 95 (8): 999–1000. doi:10.1002/ajh.25793. PMC 7228283. PMID 32212392.
- ^ a b c d e f Satturwar S, Fowkes M, Farver C, Wilson AM, Eccher A, Girolami I, et al. (May 2021). "Postmortem Findings Associated With SARS-CoV-2: Systematic Review and Meta-analysis". The American Journal of Surgical Pathology. 45 (5): 587–603. doi:10.1097/PAS.0000000000001650. PMC 8132567. PMID 33481385. S2CID 231679276.
- ^ Maier BF, Brockmann D (May 2020). "Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China". Science. 368 (6492): 742–746. arXiv:2002.07572. Bibcode:2020Sci...368..742M. doi:10.1126/science.abb4557. PMC 7164388. PMID 32269067. ("... initial exponential growth expected for an unconstrained outbreak.")
- ^ "Viral Load Exposure Factors". ReallyCorrect.com.
- ^ "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". U.S. Centers for Disease Control and Prevention (CDC). 28 June 2020.
- ^ "Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission". COVID-19 Published Science and Research. U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 30 October 2020.
- ^ Centers for Disease Control and Prevention (5 April 2020). "What to Do if You Are Sick". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 14 February 2020. Retrieved 24 April 2020.
- ^ "Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment". U.S. Centers for Disease Control and Prevention (CDC). 10 March 2020. Archived from the original on 11 March 2020. Retrieved 11 March 2020.
- ^ "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Retrieved 2 December 2020.
- ^ Mueller B (2 December 2020). "U.K. Approves Pfizer Coronavirus Vaccine, a First in the West". The New York Times. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
- ^ "COVID-19 Treatment Guidelines". nih.gov. National Institutes of Health. Retrieved 21 April 2020.
- ^ a b Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (March 2020). "How will country-based mitigation measures influence the course of the COVID-19 epidemic?". Lancet. 395 (10228): 931–934. doi:10.1016/S0140-6736(20)30567-5. PMC 7158572. PMID 32164834.
A key issue for epidemiologists is helping policy makers decide the main objectives of mitigation – e.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies.
- ^ Wiles S (14 March 2020). "After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means". The Spinoff. Archived from the original on 26 March 2020. Retrieved 13 March 2020.
- ^ "Wear masks in public says WHO, in update of COVID-19 advice". Reuters. 5 June 2020. Retrieved 3 July 2020.
- ^ a b c "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 17 April 2020.
- ^ a b "Using face masks in the community – Technical Report" (PDF). ECDC. 8 April 2020.
- ^ "Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2". U.S. Centers for Disease Control and Prevention (CDC). 10 November 2020.
- ^ Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer L (April 2020). "Face masks for the public during the covid-19 crisis". BMJ. 369: m1435. doi:10.1136/bmj.m1435. PMID 32273267. S2CID 215516381.
- ^ "Caring for Someone Sick at Home". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 3 July 2020.
- ^ "Using Personal Protective Equipment (PPE)". U.S. Centers for Disease Control and Prevention (CDC). 11 June 2020. Retrieved 4 July 2020.
- ^ a b c CDC (11 February 2020). "Scientific Brief: SARS-CoV-2 Transmission". U.S. Centers for Disease Control and Prevention (CDC). Retrieved 10 May 2021.
- ^ "Transmission of COVID-19". European Centre for Disease Prevention and Control. 7 September 2020. Retrieved 14 October 2020.
- ^ a b National Center for Immunization and Respiratory Diseases (NCIRD) (9 July 2020). "COVID-19 Employer Information for Office Buildings". U.S. Centers for Disease Control and Prevention (CDC). Retrieved 9 July 2020.
- ^ WHO's Science in 5 on COVID-19 - Ventilation - 30 October 2020. World Health Organization (WHO). 30 October 2020. Archived from the original on 25 October 2022. Retrieved 8 December 2022 – via YouTube.
- ^ Somsen GA, van Rijn C, Kooij S, Bem RA, Bonn D (July 2020). "Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission". The Lancet. Respiratory Medicine. Elsesier. 8 (7): 658–659. doi:10.1016/S2213-2600(20)30245-9. PMC 7255254. PMID 32473123.
- ^ Lipinski T, Ahmad D, Serey N, Jouhara H (1 November 2020). "Review of ventilation strategies to reduce the risk of disease transmission in high occupancy buildings". International Journal of Thermofluids. 7–8: 100045. doi:10.1016/j.ijft.2020.100045. ISSN 2666-2027. S2CID 221642242.
- ^ "Social distancing: what you need to do – Coronavirus (COVID-19)". nhs.uk. 2 June 2020. Retrieved 18 August 2020.
- ^ "Advice for the public on COVID-19 – World Health Organization". World Health Organization (WHO). Retrieved 18 August 2020.
- ^ "COVID-19 and Your Health". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 23 March 2021.
To prevent the spread of germs, including COVID-19, CDC recommends washing hands with soap and water whenever possible because it reduces the amount of many types of germs and chemicals on hands. But if soap and water are not readily available, using a hand sanitizer with at least 60% alcohol can help you avoid getting sick and spreading germs to others.
- ^ "WHO-recommended handrub formulations". WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. World Health Organization (WHO). 19 March 2009. Retrieved 19 March 2020.
- ^ Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. (September 2020). "Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review". The Cochrane Database of Systematic Reviews. 2020 (9): CD013574. doi:10.1002/14651858.CD013574.pub2. ISSN 1469-493X. PMC 8133397. PMID 33959956.
- ^ Qian M, Jiang J (May 2020). "COVID-19 and social distancing". Zeitschrift für Gesundheitswissenschaften = Journal of Public Health. 30 (1): 259–261. doi:10.1007/s10389-020-01321-z. PMC 7247774. PMID 32837835.
- ^ a b Hawks L, Woolhandler S, McCormick D (August 2020). "COVID-19 in Prisons and Jails in the United States". JAMA Internal Medicine. 180 (8): 1041–1042. doi:10.1001/jamainternmed.2020.1856. PMID 32343355.
- ^ Waldstein D (6 May 2020). "To Fight Virus in Prisons, C.D.C. Suggests More Screenings". The New York Times. Archived from the original on 7 May 2020. Retrieved 14 May 2020.
- ^ "How COVID-19 Spreads". U.S. Centers for Disease Control and Prevention (CDC). 18 September 2020. Archived from the original on 19 September 2020. Retrieved 20 September 2020.
- ^ Goldman E (August 2020). "Exaggerated risk of transmission of COVID-19 by fomites". The Lancet. Infectious Diseases. 20 (8): 892–893. doi:10.1016/S1473-3099(20)30561-2. PMC 7333993. PMID 32628907.
- ^ Weixel N (5 April 2021). "CDC says risk of COVID-19 transmission on surfaces 1 in 10,000". The Hill. Retrieved 19 December 2021.
- ^ a b "Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments". U.S. Centers for Disease Control and Prevention (CDC). 5 April 2021. Archived from the original on 5 April 2021.
- ^ a b Pedreira A, Taşkın Y, García MR (January 2021). "A Critical Review of Disinfection Processes to Control SARS-CoV-2 Transmission in the Food Industry". Foods. 10 (2): 283. doi:10.3390/foods10020283. PMC 7911259. PMID 33572531. S2CID 231900820.
- ^ Rezasoltani S, Yadegar A, Hatami B, Asadzadeh Aghdaei H, Zali MR (2020). "Antimicrobial Resistance as a Hidden Menace Lurking Behind the COVID-19 Outbreak: The Global Impacts of Too Much Hygiene on AMR". Frontiers in Microbiology. 11: 590683. doi:10.3389/fmicb.2020.590683. PMC 7769770. PMID 33384670.
- ^ Thompson D (8 February 2021). "Hygiene Theater Is Still a Huge Waste of Time". The Atlantic. Retrieved 27 February 2021.
- ^ Thompson D (27 July 2020). "Hygiene Theater Is a Huge Waste of Time". The Atlantic. Retrieved 27 February 2021.
- ^ a b c d e f g Bueckert M, Gupta R, Gupta A, Garg M, Mazumder A (November 2020). "Infectivity of SARS-CoV-2 and Other Coronaviruses on Dry Surfaces: Potential for Indirect Transmission". Materials. 13 (22): 5211. Bibcode:2020Mate...13.5211B. doi:10.3390/ma13225211. PMC 7698891. PMID 33218120.
- ^ Bhardwaj R, Agrawal A (November 2020). "How coronavirus survives for days on surfaces". Physics of Fluids. 32 (11): 111706. Bibcode:2020PhFl...32k1706B. doi:10.1063/5.0033306. PMC 7713872. PMID 33281435.
- ^ Chatterjee S, Murallidharan JS, Agrawal A, Bhardwaj R (February 2021). "Why coronavirus survives longer on impermeable than porous surfaces". Physics of Fluids. 33 (2): 021701. Bibcode:2021PhFl...33b1701C. doi:10.1063/5.0037924. PMC 7978145. PMID 33746485.
- ^ CDC (11 February 2020). "Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). Retrieved 12 April 2021.
- ^ Anthes E (8 April 2021). "Has the Era of Overzealous Cleaning Finally Come to an End?". The New York Times. Archived from the original on 28 December 2021. Retrieved 12 April 2021.
- ^ "Interim Recommendations for US Community Facilities with Suspected/Confirmed Coronavirus Disease 2019". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 4 April 2020.
- ^ "Yes, UV phone sanitizers work. That doesn't mean you need one". The Washington Post. 16 February 2021. Retrieved 29 April 2022.
- ^ Patiño-Lugo DF, Vélez M, Velásquez Salazar P, Vera-Giraldo CY, Vélez V, Marín IC, et al. (June 2020). "Non-pharmaceutical interventions for containment, mitigation and suppression of COVID-19 infection". Colombia Medica. 51 (2): e4266. doi:10.25100/cm.v51i2.4266. PMC 7518730. PMID 33012884.
- ^ "COVID-19 Informational Resources for High-Risk Groups | Keeping Education ACTIVE | Partnership to Fight Chronic Disease". fightchronicdisease.org. Retrieved 31 May 2020.
- ^ "Quarantine and Isolation". U.S. Centers for Disease Control and Prevention (CDC). 29 July 2021. Retrieved 12 August 2021.
- ^ a b c Burns J, Movsisyan A, Stratil JM, Biallas RL, Coenen M, Emmert-Fees KM, et al. (Cochrane Public Health Group) (March 2021). "International travel-related control measures to contain the COVID-19 pandemic: a rapid review". The Cochrane Database of Systematic Reviews. 2021 (3): CD013717. doi:10.1002/14651858.CD013717.pub2. PMC 8406796. PMID 33763851. S2CID 232356197.
- ^ "COVID Treatment Guidelines: Clinical Management Summary". NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 8 April 2022. Archived from the original on 5 November 2021. Retrieved 19 April 2022.
- ^ Wise, Jeff (17 April 2022). "What Happened to Paxlovid, the COVID Wonder Drug?". Intelligencer. Archived from the original on 19 April 2022. Retrieved 19 April 2022.
- ^ Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW (July 2021). "SARS-CoV-2 Antiviral Therapy". Clinical Microbiology Reviews. 34 (4): e0010921. doi:10.1128/CMR.00109-21. PMC 8404831. PMID 34319150. S2CID 236472654.
- ^ Fisher D, Heymann D (February 2020). "Q&A: The novel coronavirus outbreak causing COVID-19". BMC Medicine. 18 (1): 57. doi:10.1186/s12916-020-01533-w. PMC 7047369. PMID 32106852.
- ^ Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (May 2020). "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province". Chinese Medical Journal. 133 (9): 1025–1031. doi:10.1097/CM9.0000000000000744. PMC 7147277. PMID 32044814.
- ^ Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B (March 2020). "Comorbidities and multi-organ injuries in the treatment of COVID-19". Lancet. Elsevier BV. 395 (10228): e52. doi:10.1016/s0140-6736(20)30558-4. PMC 7270177. PMID 32171074.
- ^ Wang Y, Wang Y, Chen Y, Qin Q (March 2020). "Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures". Journal of Medical Virology. 92 (6): 568–576. doi:10.1002/jmv.25748. PMC 7228347. PMID 32134116.
- ^ "Coronavirus". WebMD. Archived from the original on 1 February 2020. Retrieved 1 February 2020.
- ^ Martel J, Ko YF, Young JD, Ojcius DM (May 2020). "Could nasal breathing help to mitigate the severity of COVID-19". Microbes and Infection. 22 (4–5): 168–171. doi:10.1016/j.micinf.2020.05.002. PMC 7200356. PMID 32387333.
- ^ "Coronavirus recovery: breathing exercises". www.hopkinsmedicine.org. Johns Hopkins Medicine. Archived from the original on 11 October 2020. Retrieved 30 July 2020.
- ^ Wang L, Wang Y, Ye D, Liu Q (March 2020). "Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence". International Journal of Antimicrobial Agents. 55 (6): 105948. doi:10.1016/j.ijantimicag.2020.105948. PMC 7156162. PMID 32201353.
- ^ U.S. Centers for Disease Control and Prevention (5 April 2020). "What to Do if You Are Sick". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 14 February 2020. Retrieved 24 April 2020.
- ^ "Update to living WHO guideline on drugs for covid-19". BMJ (Clinical Research Ed.). 371: m4475. November 2020. doi:10.1136/bmj.m4475. ISSN 1756-1833. PMID 33214213. S2CID 227059995.
- ^ "Q&A: Dexamethasone and COVID-19". World Health Organization (WHO). Archived from the original on 11 October 2020. Retrieved 11 July 2020.
- ^ "Home". National COVID-19 Clinical Evidence Taskforce. Archived from the original on 11 October 2020. Retrieved 11 July 2020.
- ^ Motseki, Thabiso Patrick (7 June 2022). "COVID-19 Vaccination Guidelines". www.nih.gov. National Institutes of Health. Archived from the original on 19 January 2021. Retrieved 18 January 2021.
- ^ Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (April 2020). "Clinical Characteristics of Coronavirus Disease 2019 in China". The New England Journal of Medicine. Massachusetts Medical Society. 382 (18): 1708–1720. doi:10.1056/nejmoa2002032. PMC 7092819. PMID 32109013.
- ^ Henry BM (April 2020). "COVID-19, ECMO, and lymphopenia: a word of caution". The Lancet. Respiratory Medicine. Elsevier BV. 8 (4): e24. doi:10.1016/s2213-2600(20)30119-3. PMC 7118650. PMID 32178774.
- ^ Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al. (2021). "Immunopathogenesis and treatment of cytokine storm in COVID-19". Theranostics. 11 (1): 316–329. doi:10.7150/thno.49713. PMC 7681075. PMID 33391477.
- ^ Doshi P (October 2020). "Will covid-19 vaccines save lives? Current trials aren't designed to tell us". BMJ. 371: m4037. doi:10.1136/bmj.m4037. PMID 33087398. S2CID 224817161.
- ^ a b Palmieri L, Andrianou X, Barbariol P, Bella A, Bellino S, Benelli E, et al. (22 July 2020). Characteristics of SARS-CoV-2 patients dying in Italy Report based on available data on July 22nd, 2020 (PDF) (Report). Istituto Superiore di Sanità. Retrieved 4 October 2020.
- ^ Tzoulis P, Waung JA, Bagkeris E, Hussein Z, Biddanda A, Cousins J, et al. (May 2021). "Dysnatremia is a Predictor for Morbidity and Mortality in Hospitalized Patients with COVID-19". The Journal of Clinical Endocrinology and Metabolism. 106 (6): 1637–1648. doi:10.1210/clinem/dgab107. PMC 7928894. PMID 33624101.
- ^ Tzoulis P, Grossman AB, Baldeweg SE, Bouloux P, Kaltsas G (September 2021). "MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management". European Journal of Endocrinology. 185 (4): R103–R111. doi:10.1530/EJE-21-0281. PMC 8428074. PMID 34370712.
- ^ Baranovskii DS, Klabukov ID, Krasilnikova OA, Nikogosov DA, Polekhina NV, Baranovskaia DR, et al. (December 1975). "Letter: Acid secretion by gastric mucous membrane". The American Journal of Physiology. 229 (6): 21–25. doi:10.1080/03007995.2020.1853510. PMC 7738209. PMID 33210948. S2CID 227065216.
- ^ Christensen B, Favaloro EJ, Lippi G, Van Cott EM (October 2020). "Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19)". Seminars in Thrombosis and Hemostasis. 46 (7): 845–849. doi:10.1055/s-0040-1715458. PMC 7645834. PMID 32877961.
- ^ "Living with Covid19". NIHR Themed Reviews. National Institute for Health Research. 15 October 2020. doi:10.3310/themedreview_41169.
- ^ a b "How long does COVID-19 last?". UK COVID Symptom Study. 6 June 2020. Retrieved 15 October 2020.
- ^ "Summary of COVID-19 Long Term Health Effects: Emerging evidence and Ongoing Investigation" (PDF). University of Washington. 1 September 2020. Archived from the original (PDF) on 18 December 2020. Retrieved 15 October 2020.
- ^ "Long-term symptoms of COVID-19 'really concerning', says WHO chief". UN News. 30 October 2020. Retrieved 7 March 2021.
- ^ "Coronavirus disease 2019 (COVID-19) – Prognosis". BMJ. Retrieved 15 November 2020.
- ^ Lavery AM, Preston LE, Ko JY, Chevinsky JR, DeSisto CL, Pennington AF, et al. (November 2020). "Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission – United States, March–August 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (45): 1695–1699. doi:10.15585/mmwr.mm6945e2. PMC 7660660. PMID 33180754.
- ^ Vardavas CI, Nikitara K (March 2020). "COVID-19 and smoking: A systematic review of the evidence". Tobacco Induced Diseases. 18: 20. doi:10.18332/tid/119324. PMC 7083240. PMID 32206052.
- ^ a b c Engin AB, Engin ED, Engin A (August 2020). "Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking". Environmental Toxicology and Pharmacology. 78: 103411. doi:10.1016/j.etap.2020.103411. PMC 7227557. PMID 32422280.
- ^ Setti L, Passarini F, De Gennaro G, Barbieri P, Licen S, Perrone MG, et al. (September 2020). "Potential role of particulate matter in the spreading of COVID-19 in Northern Italy: first observational study based on initial epidemic diffusion". BMJ Open. 10 (9): e039338. doi:10.1136/bmjopen-2020-039338. PMC 7517216. PMID 32973066.
- ^ Wu X, Nethery RC, Sabath MB, Braun D, Dominici F (November 2020). "Air pollution and COVID-19 mortality in the United States: Strengths and limitations of an ecological regression analysis". Science Advances. 6 (45): eabd4049. Bibcode:2020SciA....6.4049W. doi:10.1126/sciadv.abd4049. PMC 7673673. PMID 33148655.
- ^ Pansini R, Fornacca D (June 2021). "Early Spread of COVID-19 in the Air-Polluted Regions of Eight Severely Affected Countries". Atmosphere. 12 (6): 795. Bibcode:2021Atmos..12..795P. doi:10.3390/atmos12060795.
- ^ Comunian S, Dongo D, Milani C, Palestini P (June 2020). "Air Pollution and Covid-19: The Role of Particulate Matter in the Spread and Increase of Covid-19's Morbidity and Mortality". International Journal of Environmental Research and Public Health. 17 (12): 4487. doi:10.3390/ijerph17124487. PMC 7345938. PMID 32580440.
- ^ Domingo JL, Marquès M, Rovira J (September 2020). "Influence of airborne transmission of SARS-CoV-2 on COVID-19 pandemic. A review". Environmental Research. 188: 109861. Bibcode:2020ER....188j9861D. doi:10.1016/j.envres.2020.109861. PMC 7309850. PMID 32718835.
- ^ "COVID-19: Who's at higher risk of serious symptoms?". Mayo Clinic.
- ^ Tamara A, Tahapary DL (July 2020). "Obesity as a predictor for a poor prognosis of COVID-19: A systematic review". Diabetes & Metabolic Syndrome. 14 (4): 655–659. doi:10.1016/j.dsx.2020.05.020. PMC 7217103. PMID 32438328.
- ^ Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. (July 2020). "Obesity – A risk factor for increased COVID-19, severity and lethality (Review)". Molecular Medicine Reports. 22 (1): 9–19. doi:10.3892/mmr.2020.11127. PMC 7248467. PMID 32377709.
- ^ Roca-Fernández A, Dennis A, Nicholls R, McGonigle J, Kelly M, Banerjee R, et al. (29 March 2021). "Hepatic Steatosis, Rather Than Underlying Obesity, Increases the Risk of Infection and Hospitalization for COVID-19". Frontiers in Medicine. 8: 636637. doi:10.3389/fmed.2021.636637. ISSN 2296-858X. PMC 8039134. PMID 33855033.
- ^ "Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020.
- ^ Devresse A, Belkhir L, Vo B, Ghaye B, Scohy A, Kabamba B, et al. (November 2020). "COVID-19 Infectio